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Thesis:
December 2009
In Africa alone, Plasmodium, the causative agent of malaria is estimated to kill
a child, under the age of five every thirty seconds140. The ability of the parasite
to rapidly attain resistance, has resulted in immunity of the parasite to all,
except one group of frontline drugs. The need to develop novel drugs, vaccines
and prevention strategies that are accessible and affordable for third world
countries is of the utmost importance to prevent needless human suffering and
death.
The glycolytic pathway is an attractive drug target since it is the principal
source of ATP for the parasite. Many of the glycolytic enzymes have been
studied and proposed as drug targets, but the importance of these enzymes
for the function of the pathway as a whole has not been considered. It is
known, from the frameworks of metabolic control analysis, that control of the
flux and metabolite concentration can be divided among the individual steps.
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Differential control analysis of Plasmodium and erythrocyte glycolysis may
reveal potential drug targets. These analyses require a detailed kinetic model
of Plasmodium glycolysis, and the feasibility of constructing and validating
such a model was the aim of this study.
In this work we determined the feasibility of constructing and validating a
detailed kinetic model for the Plasmodium falciparum glycolytic pathway.
Whether the construction and validation of this kinetic model was feasible
or not was decided on the basis of the ability to: i) culture and isolate
sufficient asexual parasites for enzymatic and steady state assays , ii) obtain
kinetic parameters such as Km and Vmax for each glycolytic enzyme, either
from literature or experimentally, iii) measure glycolytic fluxes, iv) determine
glycolytic intermediate concentrations, v) construct a kinetic model from the
kinetic parameters and vi) validate it with steady state glycolytic fluxes and
metabolite concentrations
Each of the above criteria were successfully addressed. In summary, the
kinetic parameters and glycolytic fluxes that were measured experimentally,
were used to construct and partially validate a detailed kinetic model,
respectively. Further validation of the model by means of steady state
metabolite concentrations was shown to be possible with the development of
a suitable protocol to measure the glycolytic intermediate concentrations.
The model presented in this work may play an important role in drug
target identification and improving the current understanding of host-parasite
interactions and glycolytic regulation.
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Plasmodium, die parasiet wat malaria veroorsaak, is in Afrika alleen elke
dertig sekondes verantwoordelik vir die afsterwe van ’n kind jonger as vyf
jaar. Die parasiet se vermoë om vinnig weerstand op te bou het daartoe
gelei dat Plasmodium weerstandbiedend is teen byna alle nuwe teen-malaria
middels, behalwe vir ’n enkele toonaangewende groep. Die ontwikkeling van
nuwe malaria teen-middels is van uiterste belang om lyding te voorkom.
’n Goeie teiken vir teen-malaria middels is die glikolitiese padweg omdat die´
metaboliese padweg essensieël is vir die produksie van ATP, die energiebron
van die parasiet. Desondanks die feit dat meeste van die glikolitiese ensieme al
goed bestudeer en as teiken voorgestel is, is dit steeds onduidelik hoe hierdie
ensieme saam funksioneer om die metaboliese weg, as geheel, tot stand te bring.
Metaboliese kontrole analise het aangetoon dat die glikolitiese beheer verdeel
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is tussen die onderskeie glikolitiese ensieme, m.a.w. geen enkele ensiematiese
stap het volledige beheer oor die fluksie van die glikolitiese padweg nie. Die
afsonderlike analise en vergelyking van Plasmodium - en rooibloedselglikolise
met behulp van differensiële metaboliese kontrole analise sal moontlik gebruik
kan word om gasheervriendelike teikens vir nuwe middels aan te toon. So
’n analise benodig ’n omvattende kinetiese model van Plasmodium glikolise.
Derhalwe was die doel van hierdie studie om vas te stel hoe uitvoerbaar dit is
om ’n kinetiese model van Plasmodium glikolise te konstrueer en te valideer.
Die uitvoerbaarheid van die konstruksie en validering van die kinetiese
model was geasseseer op grond van die vermoë om: i) parasietkulture te
kweek en genoegsame parasiete, wat in die aseksuele fase is, te isoleer
sodat ensiembepalings en bestendige toestand-bepalings gedoen kan word, ii)
kinetiese parameters soos Km - en Vmax-waardes vir elke glikolitiese ensiem,
hetsy vanuit literatuur of eksperimentele werk, te verkry, iii) glikolitiese fluksie
te meet, iv) glikolitiese intermediaatkonsentrasies te bepaal, v) ’n kinetiese
model van die bepaalde kinetiese parameters op te stel en vi) die model te
valideer met glikolitiese flukswaardes en metaboliet- konsentrasies wat in die
bestendige toestand verkry is.
Elk van die bogenoemde kriteria was met sukses in hierdie studie aange-
spreek. Ter opsomming, die eksperimenteel bepaalde kinetiese parameters
en glikolietiese flukswaardes was gebruik om onderskeidelik ’n gedetaileerde
kinetiese model te konstrueer en gedeeltelik te valideer. Daar was getoon
dat verdere validering van die model deur middel van bestendige toestand
metabolietkonsentrasies moontlik is met die ontwikkeling van ’n geskikte
protokol om glikolitiese intermediaatkonsentrasies te meet. Die model, soos
opgestel in hierdie studie, kan moontlik ’n belangrike rol speel om teikens vir
nuwe malaria teen-middels te identifiseer en om gasheer-parasiet interaksies en
glikolitiese regulering beter te verstaan.
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Chapter 1
General Introduction
Malaria, caused by the Plasmodium species, is transmitted by the bite of a
female Anopheles mosquito and has plagued the human race for millenia. It is
estimated that in Africa alone, Plasmodium (especially P. falciparum) kills a
child under the age of 5, every 30 seconds140. Intensive insecticide spraying and
the discovery of chloroquine completely eradicated malaria from Europe and
North America. The hopes of global eradication, however, were dashed as the
parasite adapted remarkably rapidly, becoming resistant to insecticides and
overcoming drug therapy. The latter has been overcome so effectively, that
some strains are resistant to all but one (artemisinin) frontline antimalarial
drugs140. Globally, researchers are attempting to discover novel methods of
overcoming Plasmodium infections by targeting the parasite in both mosquito
and human hosts. The advent of genomics, proteomics, and metabolomics;
relatively new disciplines whose results can be integrated in systems biology
approaches, has allowed researchers to search for targets on a much broader
scale, making it possible to analyse complete pathways or even systems at
cellular and organ level.
Carbohydrate metabolism, particularly the glycolytic pathway is potentially an
excellent drug target, since the parasite derives most, if not all of its ATP from
the pathway52. As such, several targets in this pathway have been proposed.
The hexose transporter109, aldolase157, triosephosphate isomerase112, lactate
dehydrogrenase14 have all been well studied and suggested as potential drug
targets. Although researchers have looked at these enzymes in isolation, to
1
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date the glycolytic pathway of none of the Plasmodium species has been
studies as a whole. Through the theoretical framework of metabolic control
analysis we now know that instead of a single rate limiting step, control of
the flux and intermediate metabolite concentrations can be divided among the
individual steps. Obviously, enzymes which exert a large control on the flux
and intermediates would present preferential targets to those exerting a low
control. Since the parasite is a eukaryotic organism, its glycolytic enzymes
would be expected in many cases, to have high homology to the human
enzymes. As such, compounds targeting the parasite glycolytic enzymes could
potentially be toxic to the human. If, however, an enzyme in the host pathway
has low control and the corresponding parasite enzyme has a high control, the
drug would have to be less selective, as inhibition of the host enzyme would
have little effect on the host compared to the parasite. This differential control
can play an important role in drug target identification.
1.1 Project Outline
The aim of this study was to establish the feasibility of constructing and
validating a detailed kinetic model of glycolysis in the asexual Plasmodium
falciparum.
The project consisted of both experimental and theoretical aspects, each with
distinctive criteria to be met in order to establish the feasibility of creating
and validating the kinetic model.
The criteria for the experimental aspects included the ability to i) establish
cultures of asexual P. falciparum D10 and isolate sufficient trophozoites for
kinetic and steady state assays, ii) obtain kinetic parameters for the glycolytic
enzymes experimentally or from literature and iii) measure steady state fluxes
and metabolite concentrations.
The criteria for the theoretical aspects of the project included the ability to
i) construct and ii) validate the kinetic model using the determined kinetic
parameters and steady state fluxes and metabolite concentrations, respectively.
The study is presented in experimental and theoretical categories and the
aims can be summarised as follows:
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The experimental work consisted of:
• The maintenance of asexual Plasmodium falciparum D10 cultures for the
isolation of trophozoites.
• An extensive literature search for kinetic parameters for each glycolytic
enzyme in Plasmodium.
• The kinetic characterisation of as many of the glycolytic enzymes as
possible under in vivo conditions.
• The development of a method for the measurement of steady state fluxes
and internal metabolite concentrations in P. falciparum trophozoites.
The theoretical work was comprised of:
• The construction of a kinetic model using the determined kinetic
parameters.
• The partial validation of the model using steady state flux data obtained
in this study.
• Brief model analysis.
Overall the construction of a detailed kinetic model of P. falciparum glycolysis
would provide a better fundamental understanding of Plasmodium glycolysis,
but more importantly it could be used as a tool for more applied studies.
Such studies would include 1) comparing the distribution of metabolic control
found in P. falciparum to that of the erythrocyte and 2) investigating the
effect of parasite infection on the energy metabolism of the erythrocyte host
in terms of metabolic flux and control. These studies may be important for
drug target indentification and improving the current understanding of patient
pathophysiology, respectively.
Chapter 2
Review of Plasmodium Life
Cycle, History and Carbon
Metabolism
The human malarial parasite has been extremely successful in evading the
immune systems of its human and mosquito hosts. The emergence of
resistance, to all but one group of frontline drugs, has necessitated the search
for novel anti-malarials, vaccines and preventative measures. The following
review covers the Plasmodium life cycle, gives a historical overview of its
discovery and treatment and is followed by a comprehensive literature study
of the asexual Plasmodium energy metabolism. The energy metabolism, being
the subject of this thesis, consists of glycolysis, the pentose phosphate pathway,
tricarboxylic acid cycle and some ancillary pathways. Each is examined with
specific focus on the enzymes and their kinetic characterisation. The aim of
this review is to familiarise the reader with Plasmodium, its history, treatment
and energy metabolism.
2.1 Plasmodium Life Cycle
Traditionally four species of malaria, Plasmodium vivax, malariae, falciparum
and ovale, are capable of infecting humans. Recently a fifth, the simian
P. knowlessi has also been identified in humans34. The malarial parasite
4
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is transmitted by the bite of an infected female Anopheles mosquito, which
contains the sporozoite form of the parasite within its salivary glands97. An
estimated 15-200 sporozoites are injected by the mosquito154, which remain
at the bite site for 5-15 min134. Sporozoites migrate through the dermis
to a blood vessel and circulate until they reach the liver. They infect
hepatocytes by crossing the sinusoidal cellular layer separating the blood and
liver parenchyma97. This entire migration from skin to liver may be as short
as 20 minutes97. The speed and selectivity of this process have indicated that
sporozoite invasion of hepatocytes involves parasite-encoded surface proteins
and host molecules51. The sporozoites form liver schizonts, which undergo
schizogony - a series of nuclear divisions followed by cytokinesis152. Each
mature schizont may, thus, release thousands of invasive merozoites into the
blood stream102. Plasmodium vivax has a dormant, hypnozoite, stage where
sporozoites can persist for long periods without undergoing schizogony97. The
released merozoites invade erythrocytes, thereby initiating the asexual cycle of
the parasite.
Within the erythrocyte, merozoites develop into trophozoites. The early
trophozoite form is known as the ring stage. Trophozoites ingest the abundant
haemoglobin of their host by an endocytic process152. After almost complete
consumption of the erythrocyte, trophozoites undergo further schizogony and
form multinucleated blood-stage schizonts. The latter undergo cell division
to form up to 32 merozoites152. Rupturing of erythrocytes releases numerous
merozoites, which consequently invade new erythrocytes.
During the asexual blood cycle not all parasites form merozoites, as some
develop into male and female gametocytes78. These precursors of the
gametocytes are dormant and are only activated if they are ingested by an
Anopheles mosquito during a blood meal78. The formation of gametes within
the mosquito midgut is followed by fertilization, resulting in a diploid zygote.
The zygote undergoes a single round of meiotic division and develops into
a motile ookinete, which penetrates the midgut and forms an oocyst on the
basolateral lamina78. After growth and development, the oocyst may contain
more than 10 000 sporozoites, which invade the salivary glands78 and thus
complete a full cycle.
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2.2 Historical Overview: Plasmodium discovery and
treatment history
Malaria, ague and "marsh fever" are just a few names for the disease which has
plagued civilisations for millennia. Throughout the world, moist areas below
2000m in altitude and between the tropics of Capricorn and Cancer have been
subject to malaria invasion11.
Before the cause of malaria was known, the trademark and often fatal tertiary
and quaternary chills and fevers of malaria were greatly feared. Romans and
Greeks ascribed the fevers to different quantities of heat producing bile58,
or the presence of black bile which was supposedly released by the spleen65.
Remedies thus predominantly consisted of phlebotomies and rest. Others
believed that the fevers had divine origin58 or that ’noxious air’, which was
typically found around insect plagued marshes, was responsible65. These
beliefs and the fact that mosquito transmission was unsuspected hampered
the discovery of a cure, as well as prevented the recruitment of mosquito
preventative measures.
The extent to which malaria has impacted human history is debatable, but it
certainly played a large role in European history, where it is held responsible
for depopulation of important regions of early Rome as well as altering land
utilisation methods in Italy58. Additionally, across Europe large tracts of land
near marshes, swamp and coastal deltas had been rendered uninhabitable65.
This highlights the significance of the discovery of the miraculous ’fever bark’
during the early 1600’s.
The bark of the cinchona tree (Cinchona spp) contains, amongst others, the
alkaloid quinine, which cured malaria. The discovery of the foul-tasting and
bitter bark is itself incredible since the tree was first discovered in the high
foothills of the Andes where malaria never existed115. Twenty three Cinchona
spp are known, although some scholars argue that eight of these are variants
and thus only fifteen species occur65. It is known, however, that the quinine
content differs substantially between species65,115. How or by whom the
therapeutic effects of cinchona bark were discovered is not known exactly.
Numerous legends exist, but discrepancies and irregularities go a long way in
discrediting them65. Whether it was discovered by native South Americans,
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the Jesuits or Spanish invaders is perhaps of little consequence compared to the
magnitude of the discovery itself. Unfortunately, even though a bark infusion
was successfully used to treat and cure infected patients in the early 1600’s,
the ’Peruvian bark’, or ’Jesuits bark’ was treated with skepticism in Europe
and only gained widespread recognition as a cure for the ague during the late
1600’s65.
Once the bark was finally recognised as the malarial cure, the British, Dutch
and Indian governments imported huge quantities of bark from South America
to counter the widespread prevalence of malaria amongst their numerous
colonies. The limited and unreliable cinchona bark supply from South America
all but forced Britain, Netherlands, India and later the United States to go to
great lengths to acquire plants and establish vast cinchona plantations. For
an in depth coverage of the history of the cinchona discovery, procuration and
cultivation, I refer the reader to The fever trail: In search of the cure for
malaria 65.
In 1876 Dr Patrick Manson, a medical officer discovered the filarial parasite
inside mosquitoes that had fed on soldiers infected with elephantiasis (a
parasitic infection of the filarial worm). Even though he never discovered the
transmission of the filarial worm from the mosquito to the human, he conveyed
his findings of human to mosquito transmission to Sir Ronald Ross65,115. In
1880, Alphonse Laveran discovered ’certain parasitic elements’ in his malarial
patients. Ten years later, Ross, similar to the observations of Manson and
Laveran, identified oocytes in the stomach wall of an Anopheles mosquito that
had fed on a malaria infected patient. Ross also observed the avian malaria
oocytes burst and sporozoites migrate to the salivary glands via the thoracic
cavity65,115 . These findings together with those of the malaria parasite being
found in both the insect and human proved the dual host malarial life cycle.
Ross is also responsible for fully recording the avian malaria parasite life cycle
within the mosquito. Professor Giovanni Grassi, at Rome University was the
first to note that Plasmodium was mosquito specific and the human infecting
strains were restricted to the Anopheles mosquito65,115 . In 1902, Ross received
the Nobel Prize for his malaria work.
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2.2.1 Antimalarial History
Soon after the discovery of quinine as the active compound in cinchona bark,
chemists tried to synthesise it. During the first and second world wars, malaria
ravaged troops due to the limited cinchona bark supply and the disruption of
supply lines by hostile forces. The Germans, especially were desperate to find
a synthetic compound and subsequently invested heavily in developing and
finding suitable compounds65. In 1926 a German research team discovered the
synthetic plasmochin and later in 1932, atabrine. These compounds, although
effective were toxic with unpleasant side-effects. A breakthrough came in 1934
with the discovery of the 4-amino quinolines (resochin and sontochin), which
similar to quinine, targeted the blood stage parasites, but much more rapidly65.
Strangely, the formulas for these compounds where given to the Farben’s
American sister company, Winthrop Stearns, where they were shelved. During
the second world war the shortage of quinine and the unpleasant side effects
of new synthetics such as atabrine caused French doctors to suggest to the
Americans that they look at sontochin again, since the French were using it
successfully. Through sontochin, chloroquine was discovered and found to be
identical to the resochin which had been shelved for 10 years. Chloroquine and
its derivatives are arguably, to date, the most successful antimalarials being
cheap to synthesise and highly effective against all forms of Plasmodium. In
fact the development of the effective plasmodicals as well as the development
of potent insecticides were thought to be the end of malaria plague, which is
exemplified by the statement made by W.K Blackie in his book (1947)Malaria:
With Special Reference to the African Forms 11, "The outlook for the future is
thus full of promise...".
2.3 Current Malaria Drug Status
2.3.1 Drug Resistance
For approximately 20 years, chloroquine drove malaria back. Effective patient
treatments and strict insecticide spraying regimes (notoriously with DDT)
cleared Malaria from Europe, parts of Africa and most of North America. The
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success of chloroquine was short-lived and in 1962 scientists noted resistance
occuring in Vietnam, Thailand, Cambodia and Malaya65. During the Vietnam
war, US medics started prescribing a a cocktail of chloroquine and primaquine
to US soldiers in an attempt to overcome resistance. The rapidly mutating
parasite soon rendered the cocktail ineffective.
A new line of drug was discovered and published by the Chinese in 1979.
Artemisinin obtained from Artemisia annua, also known as qing-hoa or sweet
wormwood, cured malaria, including chloroquine-resistant strains more rapidly
and with less toxicity than chloroquine65. Artemisinin and its derivatives are
currently the only drugs for which no real resistance is known, although the
emergence of slight resistance may already be occuring in Cambodia99.
To extend the therapeutic time of antimalarials the WHO suggests various
combinations of the remaining effective drugs. The original idea by WHO
to globally eradicate malaria has been replaced by the idea of ’rolling back
malaria’, which was initiated in 1998140. The Roll Back Malaria initiative
aims to slowly, using preventative measures (e.g. mosquito netting and
repellents), insecticides, education and treatment, push the boundaries of
malaria back. The ability of Plasmodium and Anopheles to develop resistance
to antimalarials and insecticides respectively, necessitates the development
of novel drugs and insecticides. The need for substantial funding for this
research is being realised with the initiation of NPOs such as, amongst others,
the Medicines for Malaria Venture (MMV) and Global Fund to fight AIDS,
Tuberculosis and Malaria (GFATM), Gates Foundation and the Wellcome
Trust.
2.3.2 Current and Future Treatment and Prevention
Regimes
2.3.2.1 Current Treatment Measures
There are three major antimalarial drug groups, namely the quinolines, pyri-
methamines and artemisinins.
Drugs predominantly target the asexual blood stage of the parasite, although
the 8-amino quinolines also target the liver stages via an unknown mechanism
of action57. P. vivax and P. ovale produce dormant hypnozoites in the liver,
which result in recurring malaria. The development of resistance to the only
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known drugs that target the liver stage of the parasite is concerning and it is
thus essential that new drugs target this stage. Development of antimalarials
that target the liver stage is challenging due to the technical difficulty of
establishing insectariums in order to produce sufficient numbers of sporozoite
infected hepatocytes57. Why drugs that are effective against the asexual phase
of the parasite are not against the sexual phase is unknown. It may be a
question of target accessibility or differing metabolism.
Several drug targets in the asexual Plasmodium stages are known. Some
have been localised to the cytosol (e.g. folate inhibitors, pyrimethane-
sulfadoxine) or specific organelles such as the mitochondrian (atovaquone,
tafenoquine), apicoplast (azithromycin, doxycycline) and digestive vacuole
(falcipain inhibitors). Quinine and its derivatives (chloroquin, quinine,
mefloquine) are thought to prevent haem detoxification and biomineralisation
by forming complexes with haem57,125. Even though such a diverse range of
sites have been targeted, resistance to all the drugs mentioned above exists,
which has lead to a dramatic increase in malaria infections. Currently the
only effective treatment is with the costly artemisinin and its derivatives
(artemether, artesumate, artemotil). WHO proposes various combinations
such as artemether / lumefantrine, artesunate / amodiaquin, artesunate /
sulphadoxine-pyremethaminm, artesunate / mefloquine and amodiaquine /
sulphadoxine-pyremethamine. These combinations have not only decreased
the treatment course time from 7 days of artemisinin monotheraphy compared
to three days of combination therapy100 teste158 , but also increase the
therapeutic time of the individual drugs. In theory two distinct modes of action
should allow the combination therapy to overcome resistance to one of the
drugs. The combination therapies are effective and well tolerated158. The real
problem with the combination therapies is that they are more expensive, with
the result that often less effective monotherapies are used. Poorer countries
thus require large amounts of donor funding if malaria is to be pushed back
and eradicated.
2.3.2.2 Malaria Prevention
The slow battle against malaria is being fought on numerous fronts including
the killing or modification of the insect vector; prevention of transmission from
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human to mosquito and vice versa and targeting sexual and asexual phases.
Malaria infection rates are directly coupled to the presence of infected female
Anopheles mosquitos. The vector population density is a function of season
and climate conditions, whereas the percentage of infected mosquitos would be
a function of the number of infected human hosts near the vector population.
Removal of the vector would, in essence, eradicate malaria, as evidenced by
the success of intensive DDT spraying in the US and Europe. The ecological
hazard of DDT, resulted in the preferred use of pyrethroid based insecticides.
Resistance to these insecticides has, however, limited their effectiveness140.
Indoor residual spraying is an effective means of removing the vector. Physical
prevention of malaria by using insecticide treated bed nets has been shown to
decrease child mortality substantially in Africa48.
Since pyrethroids are the only licenced insecticides for the use on "insecticide
treated bednets", the development of novel effective insecticides is required.
The rapid reproduction rate of Anopheles has the disadvantage that even
slight resistance to insecticides results in a rapid rebound of the vector
population25. The development of combinations of pesticides may help in
overcoming resistance for longer periods of time.
Novel methods of vector control is a field of active study. Understanding
the mechanisms by which a mosquito selects a host, may lead to a means
of attracting mosquitoes by making use of odorant receptors86. Genetic
modification of the mosquito to induce resistance to malarial infection or by
preventing development of the parasite within the mosquito may provide an
novel method of Plasmodium control39,93.
2.4 Drug Discovery
2.4.1 Future Treatment: Vaccine Development
The difficulty of distributing antimalarials, pesticides and insecticide treated
bed nets in countries with poor medical and transportation infrastructure
makes the idea of a malaria vaccine highly attractive. A vaccine that conferred
total immunity for life, after one or two immunisations, would save millions
of lives and go a long way in eradicating malaria globally. As of present the
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perfect vaccine has remained elusive, due to the parasite’s uncanny ability to
vary its surface antigens128. Progress has been made, however, in developing
vaccines against pre-erythrocytic parasites and liver stage parasites. These
stages are accompanied by low numbers of parasites compared to the asexual
phase and they do not portray clinical symptoms, which makes an appealing
vaccine target140.
Several stages of the Plasmodium life cycle within the human host, such as
transmission, pre-erythrocytic, blood stage and gametocyte stages have been
the target of vaccine development.
Pre-erythrocytic vaccines target the invading sporozoites and prevent them
from infecting the hepatocytes. This stage is a highly appealing target, since
it is asymptomatic. A promising randomised trial in Mozambique, involving
over 2000 children under the age of five, showed that the vaccine prevented
primary infection by P. falciparum by 45% and severe malaria by 58%140.
Erythrocyte stage vaccines aim to prevent the merozoite invasion of erythro-
cytes. Merozoites have a number of antigenic surface proteins, but antigen
polymorphism and the further difficulty in discovering other target antigens
has impeded successful vaccine development140. Gametocyte stage vaccines
would not aid in curing a patient, but would prevent transmission of parasite
gametocytes to a vector mosquito. Such a vaccine used in combination with
anti-malarial treatments or alternative stage vaccines would greatly aid in
reducing the Plasmodium population within the mosquito population and thus
indirectly reduce malaria infection rates.
An in depth review of malaria vaccine development is outside the scope of this
work, I therefore refer the reader to the following reviews57,128.
2.4.2 New Approach: Bioinformatics and Systems Biology
Drug discovery has progressed from the trial and error methods such as "try
this plant", through isolated active components to high throughput screening
of millions of compounds against a specific, or nonspecific target. Even though
throughput has been dramatically increased, the number of new chemical
entities reaching the market has not increased accordingly38.
The availability of large databases containing qualitative and quantitative
genomic, proteomic, metabolomic, molecular interaction data has given rise
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to the development of analytical tools to integrate the data and extract
useful information. This may lead to enhanced fundamental understanding,
hypothesis testing, biotechnological innovation and drug discovery.
Since small changes in enzyme concentration (proteome) only lead to a small
change in metabolic fluxes but may drastically alter metabolite concentrations,
it has been proposed that studying the metabolism instead of the higher
macromolecular ’omes’ provides a more sensitive measure of changes brought
about by disease or drug intervention77. Models of systems at a metabolic level
are thus useful for drug discovery. Many models of systems at a metabolic level
have been constructed and are available online for download (e.g BioModels -
http://www.ebi.ac.uk/biomodels-main/) and/or interrogation (JWS Online -
http://jjj.biochem.sun.ac.za/).
Two model analysis methods are mentioned throughout this thesis, namely
metabolic control analysis and differential control analysis. Metabolic control
analysis, founded by Kascer and Burns74 and Heinrich and Rapoport60, is a
theoretical framework which quantifies the relative control of an enzyme on
the steady state fluxes and metabolite concentrations. The framework moves
away from the simplified view of a single ’rate-limiting’ step and allows one to
quantify the control contribution of each reaction step.
Differential control analysis is the comparison of the distribution of metabolic
control in different models (e.g glycolysis models for Trypanosoma and
erythrocyte) in an attempt to identify enzymes with high control in the parasite
(Trypanosoma), but low control in the host67.
Although all current models only cover a small portion of cellular metabolism,
gene regulation, signaling pathways etc, the creation of a detailed silicon
cell or organism is the ultimate goal. This is currently not possible with
available experimental data, but models with a varying degree of detail have
been constructed for whole cells, organs, regulatory networks, cell cycles and
metabolic pathways.
It is generally accepted that Plasmodium is entirely dependent on glycolysis for
energy during the asexual stages and this pathway is thus an attractive drug
target, but its enzymes have been studied only in isolation. The construction
of detailed glycolytic kinetic model will not only improve fundamental under-
standing of the pathway in terms of its regulation, but by using differential
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control analysis can be used to identify potential drug targets.
2.5 Carbohydrate Metabolism
The malaria parasite’s life cycle is complex and divided between the vertebrate
and mosquito hosts and its carbohydrate metabolism is perfectly adapted
to supply energy and intermediates for biosynthetic purposes. This project
concentrates on the asexual stage of Plasmodium and as such this review covers
the metabolism specific to the erythrocyte stage. During the asexual stage the
erythrocyte serves two purposes: (i) as barrier from the immune system and (ii)
as a source of metabolites. The parasite multiplies asexually, whilst actively
digesting the erythrocyte haemoglobin for resources, before being released into
the blood stream and infecting more red blood cells. Although the parasite
has these salvage pathways which utilise the host resources, it is capable of
certain de novo biosynthetic pathways, such as pyrimidine biosynthesis as well
as having the ability to fix carbon dioxide.
Recently, the P. falciparum genome has been sequenced54 and partially
annotated6. However, there remains a lack of detailed knowledge regarding
parasite metabolic pathways, enzymes in these pathways and structural
information of the enzymes, has slowed the progress of innovative drug
design. Understanding metabolic pathways, their regulation and metabolic
control structures is essential for identifying key pathways and enzymes as
drug targets. Enzymatic structural information is also indispensable, as host
and parasites enzymes are often similar. Together pathway and structural
information would allow researchers to potentially design specific and selective
antimalarials, although differential control analysis between parasite and host
may reveal targets that could be targeted selectively (drug selectively targets
an enzyme), without the need for specificity (drug can inhibit both host and
pathogen enzyme).
This review explores the carbohydrate metabolism (Fig. 2.1.) of the asexual
Plasmodium and covers what is currently known about glycolysis, the pentose
phosphate pathway and how these pathways are linked, together with the
tricarboxylic acid cycle (Fig. 2.2.), to the electron transport chain. Since
these pathways are also integrally linked to carbon dioxide fixation and the
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purine salvage pathway these auxiliary pathways will also be briefly examined.
Enzymes found in these metabolic pathways will be discussed with specific
focus on their enzymatic characterisation, regulation and potential as drug
targets.
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Figure 2.1: Schematic representation glycolysis, pentose phosphate pathway
and carbon dioxide fixation in Plasmodium. The parasite and erythrocyte
compartments are shown in different shades of grey. Enzymatic steps are portrayed
as red circles and the enzyme names are shown in italics. See text for details.
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2.5.1 Glycolysis
During the asexual phases all Plasmodium species are entirely dependent on
glycolysis for ATP production132. It is for this reason that a great deal of
research has been directed at characterising the enzymes of the glycolytic
pathway (Fig. 2.1.) in an attempt to gain a better understanding of the
pathway and to develop effective inhibitors. The asexual stages of malaria store
no reduced carbon (energy) reserves and consequently the malarial parasite
utilises glucose from the host serum110,129. Glucose is rapidly taken up by
parasitised erythrocytes, where it is metabolised. In fact, upon infection
glucose uptake has been shown to increase as much as 100 fold87, inducing
a significant increase in glycolytic flux110. It is, expected, however, that
the rate of glucose uptake would be dependent on malarial species and
experimental conditions. It has been shown that P. falciparum requires glucose
or fructose161,82 for growth, and cannot utilise ribose, mannose or galactose as
a carbohydrate source87.
Nearly all glucose, used by Plasmodium, passes through the anaerobic
glycolytic pathway, with a net yield of two moles ATP and two moles lactate
per mole glucose129. Indeed, the almost total conversion of glucose to lactate
was initially presumed to indicate that the pentose phosphate pathway (PPP)
did not exist, although it is now known that there is a low flux (relative to
glycolysis) through the PPP.
The considerable increase in glucose uptake and rapid production of lactate
necessitates an efficient transport system. Sufficient glucose needs to be taken
from the blood to support the rapidly multiplying parasite. Additionally,
excessive lactate buildup in the cell is toxic and the parasite thus has an
efficient export system. Although, strictly speaking, hexose and lactate
transport would not fall under glycolysis, these transport steps are an integral
part of the pathway and thus warrant their inclusion.
2.5.1.1 Hexose transport
It has been reported that there is an approximate 100-fold increase in glucose
uptake by erythrocytes infected with maturing asexual parasites132. Glucose
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and fructose are transported into the erythrocyte via GLUT1 and GLUT5
respectively. The high density of the rapid transport protein in the erythrocyte
membrane results in a glucose transport capacity that easily supplies the
demand of the parasite80. Within the erythrocyte, the parasite has a hexose
transporter, PHT1161. This transporter was expressed in Xenopus oocytes and
shown to be a saturable, sodium-independent, and stereospecific transporter
of both glucose and fructose162. The P. vivax and P. falciparum transporters,
PvHT1 and PfHT1 respectively, have been kinetically characterised69,70,161,162.
The hexose transporters’ of P. knowlesi (simian) and P. yoelii (murine) have
also been kinetically characterised71. Immunofluorescence microscopy has
shown that PfHT1 resides in the parasite plasma membrane and not in the
erythrocyte membrane162. Glucose and fructose are thus thought to cross
the parasitophorous vacuolar membrane to the parasite plasma membrane via
high-capacity non-selective channels82.
It has been established that PfHt1 is a single copy gene with no close
homologues162. Expression of the single PfHt1 transcript varies throughout
the P. falciparum life cycle with mRNA levels peaking 8h post invasion of the
erythrocytes.162.
Inhibition of parasitic glucose uptake immediately leads to a decrease in ATP
levels161. The potential of PfHT1 as a drug target has been examined with
inhibitors in several studies71,124,69,70 and reviewed by Patel et al 109.
2.5.1.2 Lactate Transport
In uninfected erythrocytes, lactate crosses the plasma membrane to the
blood stream via three major pathways: (i) a specific H+ monocarboxylate
transporter, (ii) the band 3 anion exchanger, and (iii) by diffusion of the
protonated form across the lipid bilayer80. The capacity of these transport
systems, however, has been calculated to be inadequate for the removal of
lactate produced by Plasmodium glycolysis in parasitised erythrocytes75,80.
Studies have demonstrated that even when the aforementioned transporters are
inhibited, there is still a rapid flux across the parasite erythrocyte membrane.
This transport has been attributed to anion-selective diffusion pathways and a
lactate-proton cotransporter35,75,80. The latter has been shown be a member
of the monocarboxylate transporter (MCT) family43. Once the lactate is
transported to the erythrocyte cytosol it is exported to the bloodstream via
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the erythrocyte transporters and new anion-selective channels, induced by the
parasite35,43.
2.5.1.3 Glycolytic enzymes
"Many of the glycolytic enzymes occur as isozymes, each having different
affinity (Km) for the substrate and different Vmax as well as different regulatory
pathways"129. This is a significant factor in drug development, as inhibition
of specific isozymes may not inhibit all the isozymes and drug potency may be
reduced.
The next section will broadly review the current knowledge of the Plas-
modium glycolytic enzymes - hexokinase, phosphoglucose isomerase (PGI),
phosphofructokinase (PFK), aldolase, triose phosphate isomerase (TIM),
glyceraldehyde-phosphate dehydrogenase (GAPDH), phosphoglycerate kinase
(PGK), phosphoglycerate mutase (PGM), enolase, pyruvate kinase (PK) and
lactate dehydrogenase (LDH). Selected kinetic parameters that have been
published are tabulated at the end of the enzyme subsections in Table 2.1.
2.5.1.4 Hexokinase
The first reaction in glycolysis is catalysed by hexokinase, which phospho-
rylates glucose in an ATP dependent reaction, yielding glucose-6-phosphate
(G6P) and ADP. The hexokinase gene, in P. falciparum, is located on
chromosome 8, and is only 26% homologous to the human hexokinase104,129
and codes for a 54 kDa protein129.
Plasmodium hexokinase activity has been identified in extracts of infected ery-
throcytes119,129,132. Hexokinase activity in P. berghei isolates (thus including
erythrocyte hexokinase) was 35 times higher than in uninfected erythrocytes84.
Roth et al.119 reported that P. falciparum infected erythrocytes had a 25-fold
increase in hexokinase activity, compared to normal erythrocytes.
The enzyme has been partially kinetically characterised and it is reported
that the parasitic enzyme has a lower Km for glucose compared to human
hexokinase119. For ATP, hexokinase had a Km of 2 mM in P. berghei 84.
Regulation of this enzyme has not been studied, although glucose-6-phosphate
is known to have feedback inhibition in some instances144. It has also been
shown in the filarial roundworm, Brugia malayi, to be inhibited by ADP and
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activated by glucose-6-phosphate135.
Hexokinase has not been proposed as a drug target, although this enzyme has a
high control on the glycolytic flux in some glycolytic models and thus, together
with the poor homology to the human hexokinase, presents a potential drug
target.
2.5.1.5 Phosphoglucose Isomerase
PGI catalyses the conversion of G6P to fructose-6-phosphate (F6P). P.
falciparum isolates were shown to have three or four isozymes of PGI138. Upon
erythrocyte infection by P. falciparum, PGI activity increases 4-9 fold138.
Plasmodium PGI has a molecular mass of 66 kDA and is 34% homologous
to the human enzyme138, with the highest degree of similarity in the active
sites129. The PGI gene of P. falciparum was cloned, characterised and
expressed in E. coli. The gene was mapped to chromosome 1876. The high
homology between the parasite and host enzyme at the active sites and the fact
that PGI typically has a low metabolic control of the flux and intermediate
concentrations is probably the reason that research has not been directed at
inhibiting this enzyme. It is interesting to note, however, that antiserum raised
against the enzyme, specifically inhibits parasite PGI activity, with no observed
inhibition of the host enzyme138.
2.5.1.6 Phosphofructokinase
PFK catalyses the phosphorylation of F6P to form fructose 1, 6-bisphosphate
(F1,6BP). PFK from P. berghei has been isolated from infected erythrocytes
and kinetically characterised in detail17,18,19. PFK is regulated by various
ions and metabolites and is typically inhibited by ATP, phosphoenolpyruvate
(PEP), 2,3-bisphosphoglycerate, citrate and activated by AMP, F6P, ADP,
F1,6BP and fructose 2,6-bisphosphate148 teste17 . Plasmodium, however
appears to have a unique mode of regulation and P. berghei PFK is inhibited
strongly by ATP and Mg2+ ions and is activated by PEP, F6P and inorganic
phosphate17,18,19,20.
Various tissue specific isozymes are known for human tissues41 but whether or
not they exist within Plasmodium is unknown.
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2.5.1.7 Aldolase
Aldolase catalyses the aldol cleavage of F1,6BP into dihydroxyacetone phos-
phate (DHAP) and glyceraldehyde-3-phosphate (GAP). Both P. berghei and
P. falciparum aldolase proteins have been cloned, sequenced and expressed
in E. coli 40,96. The class I homotetrameric enzyme has a molecular mass of
160 kDa79. Only a single aldolase gene is present in Plasmodium 31. The
P. falciparum gene sequence, which codes for aldolase, is approximately 50%
homologous to the three human isozymes129.
Extremely high aldolase activity has been observed in P. falciparum infected
erythrocytes, with peak activity between 32-36 hours68,103,104. This typically
corresponds with the mature trophozoite stage, of the 48-hour blood-stage
life cycle157. The peak aldolase activity corresponded to peak aldolase mRNA
concentration, indicating transcriptional regulation157. This prompted Wanid-
woranun et al.157 to test the antiplasmodial effect of several phosphorothioate
antisense oligodeoxynucleotides (ODNs), which targeted several sites on the
aldolase gene of P. falciparum. Nanomolar concentrations of ODN, targeting
the gene splice donor site, resulted in 50% inhibition of parasitemia. It was
suggested that a combination of ODNs, targeting different sites of the gene,
might result in higher levels of inhibition157.
The aldolase crystal structure of P. falciparum 79 revealed several potential
drug targets. A specific area that differentiates the human and malarial
aldolase, is a highly variable tail in the C-terminal region110. The tail has
two consecutive Lys residues, which may be a target for drug design110.
Interestingly, substituting the two lysine residues with the corresponding host
amino acids, increased the catalytic rate68. The tail has been shown to be
important for enzymatic catalysis40, which increases its potential as a drug
target.
Another difference is the presence of the, so-called, 290s loop. The loop forms
part of a binding pocket, in conjunction with two nearby loops110. The binding
pocket appears more hydrophobic and constricted than human isozyme A110,
which may be a property that can be utilised in inhibition design. There may
be an interaction between the C-terminal tail and the binding pocket, as they
are located close together79. Designing small hydrophobic inhibitors that bind
to the binding pocket, and interact with the lysine residues, may selectively
inhibit the parasite enzyme79. It is shown that, in mammalian cells, PFK,
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aldolase and glyceraldehyde-3-phosphate (GAP) dehydrogenase are associated
with cytoskeleton elements110.
2.5.1.8 Triosephosphate isomerase
TIM catalyses the inter-conversion of DHAP and GAP. In P. falciparum the
TIM gene is located on chromosome 14. It has been cloned, sequenced and
expressed in E. coli 111. The enzyme has been partially characterised in terms
of its kinetics where the affinity of GAP was determined91. The gene has a
single intron and is 42-45% homologous to TIM genes from other sources129.
The enzyme is a dimer with a molecular mass of 28 kDa. The crystal structure
of P. falciparum TIM was resolved at 2.2 Å156. A more recent crystal structure
of TIM in complex with phosphoglycerate was resolved at 1.1 Å108. The
structures revealed several differences between the human and parasite enzyme.
Ser 96, which is conserved in most species, is replaced by Phe in the plasmodial
enzyme110. Another highly conserved charged surface residue, Glu 183 is
replaced by hydrophobic Leu in the parasite enzyme110, which exposes a
hydrophobic patch at a position adjacent to a positively charged region156.
Met 13, which is found at the dimer interface of the human enzyme, is replaced
by Cys 13156. The differences are being probed as potential drug targets as
they may potentially, offer selectivity.
Although Met 13 at the dimer interface has not been directly targeted,136
peptides, corresponding to residues 9-18 and 68-79, have been designed to
bind at the dimer interface. The peptide that contained residues 68-79 had an
IC50 range of 0.6 µM, which shows the potential of drugs designed to disrupt
subunit interactions. A hydrophobic anionic molecule targeting the surface
region of Leu 183 may specifically inhibit the parasite enzyme156. This led
Joubert et al.73 to look at anionic sulfonated dyes, some of which inhibited
TIM at concentrations of less than 100 mM.
The TIM active site has an active site loop, called loop 6 (residues 166-
176), which is capable of considerable movement and essential to catalysis108.
Phe 96 appears to impede loop closure due to a steric clash with Ile 170 in
loop 6110, although both open and closed conformations were observed in a
crystal structure of TIM-2-phosphoglycolate108. Since Phe 96 is unique to
Plasmodium and interacts with the catalytic loop, it may show great potential
as a drug target. Strategies for potentially inhibiting this enzyme are reviewed
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by Ravindra et al 112.
2.5.1.9 Glyceraldehyde-3-phosphate dehydrogenase
This enzyme catalyses the conversion of GAP, Pi and NAD to 1,3-
bisphosphoglycerate and NADH. It has been identified in the avian infecting
species, P. cathemerium and P. gallinaceum 132 and in the case of P.
falciparum, cloned and expressed in E. coli 37. The estimated 36.6 kDa protein
has 63.5% identity to the erythrocyte GAPDH37. The enzyme has not, as yet,
been kinetically characterised.
2.5.1.10 Phosphoglycerate Kinase
PGK converts 1,3-phospoglycerate to 3-phosphoglycerate. Two isoenzymes
of PGK have been isolated from P. falciparum 129. This 45kDa protein is
distinct from the host enzyme with differing isoelectric point, Km, Vmax and
immunologic epitopes129. The gene is 60% homologous to other eukaryotic
enzymes and found on chromosome 9129. Recently, the enzyme has been
kinetically characterised and crystallised106. Some inhibitory studies have been
performed and suramin was found to inhibit PGK expressed in E. coli with
an IC50 of 7 µM106.
2.5.1.11 Phosphoglycerate Mutase
The conversion of 3-phosphoglycerate to 2-phosphoglycerate is catalysed by
PGM. The parasite enzyme has not been isolated or characterised, but a
putative gene coding for PGM has been identified in P. falciparum 3D7 6.
2.5.1.12 Enolase
Enolase catalyses the inter-conversion of 2-phosphoglycerate and phospho-
enolpyruvate. Enolase activity in P. falciparum infected red cells was found to
be 15 times higher than uninfected erythrocytes129. The enolase gene has been
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isolated, characterised and been mapped to chromosome 10107,113. The gene
is 60-70% homologous to other eukaryotic enolase enzymes113. The enzyme
is a homodimer, with a molecular size of 100 kDa107. For activity, enolase
requires the binding of two bivalent cations (Mg2+ in vivo), per subunit107.
The binding at site I leads to a conformational change within the enzyme,
whereas binding at site II is essential for catalysis46. At high concentrations,
bivalent cations inhibit enzyme activity, which suggest the presence of a third
inhibitory site107. Enolase has been kinetically characterised for P. falciparum
and binding constants for both substrate and product determined. It was also
found that enolase is strongly activated by Mg2+, slightly by K+ and inhibited
by Na+ 107.
2.5.1.13 Pyruvate Kinase
Pyruvate kinase catalyses the substrate level phosphorylation of ADP, using
phosphoenolpyruvate and producing pyruvate and ATP. Pyruvate kinase
activity was identified in the P. falciparum infected human erythrocytes117
and P. berghei infected mice erythrocytes17. The enzyme activity appears to
increase over 11-fold upon infection117 and is highly regulated in protozoan
parasites, such as Toxoplasma gondii, Trypanosoma brucei and Leishmania
mexicana 44,45,90 and Plasmodium 27.
Plasmodium possesses two pyruvate kinases (PK1 and PK2), which are both
expressed during the asexual phase28. PK1 expression is constant and
continually high throughout the asexual phase, whereas PK2 expression peaks
at approximately 20h post invasion. The expression profile of PK2 appears to
follow the apicoplast lipid sythesis genes28. Since pyruvate kinase does exist
within the apicoplast109, which is the site of lipid synthesis it may be that PK2
is in fact, localised to this organelle. The isozymes have low amino sequence
identity (20%) and it appears that PK2 is unique to the Apicomplexans28
and the proteins differ in size being 55.6 and 86.6 kDa respectively. It should
be possible to determine the localisation of the isozymes using fluorescently
tagged antibodies raised against the individual isozymes.
The pyruvate kinase of P. falciparum has been cloned, isolated, kinetically
characterised and found to be competitively inhibited by ATP with respect to
PEP and non-competitively inhibited by citrate27. Pyruvate kinase appears
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not to be activated by F1,6BP27, which is a common activator in other
species150. The insensitivity to F1,6BP may be due to the Lys-Glu 418
substitution. Lys 418 is thought to be involved in the binding the 6-phosphate
moiety of F1,6BP, but the malarial enzyme has a glutamate residue in this
position27.
2.5.1.14 Lactate dehydrogenase
LDH is responsible for the recycling of NAD+ from NADH by reducing the keto
group of pyruvate to a hydroxyl group (lactate). Since the energy metabolism
is anaerobic glycolysis, the LDH of P. falciparum it has been proposed as a
potential drug target. Inhibition of LDH has been shown to kill the parasite120,
presumably by preventing the recycling of NAD+, which in turn prevents ATP
production.
P. falciparum LDH is coded by a single gene (1.6 kb mRNA) on chromosome
1322. The 316 amino acid protein has a molecular mass of 33 kDa22. The
parasitic enzyme has been extensively kinetically characterised15,26,133,160.
Although it was initially thought that LDH was not inhibited by pyruvate
as in some organisms129, it has since been found that Plasmodium LDH is
weakly inhibited by pyruvate at high concentrations with a Ki of 140mM133.
The kinetic mechanism has been determined to be an ordered bi-bi mechanism
with the coenzyme binding first133.
A wealth of structural information is available for Plasmodium and human
LDH. The crystal structure of P. vivax LDH in complex with NADH and
3-acetylpyridine adenine dinucleotide (APADH) has been determined26. The
crystal structure of P. berghei LDH has been solved to resolution of 2.3 Å160.
The crystal structures P. falciparum, P. vivax and P. brucei are highly similar,
with no significant alterations observed in the active site or cofactor-binding
pocket15,26. It is thus likely that inhibitors targeting malarial LDH would be
effective across the Plasmodium genus26. The structures of the heart (H) and
muscle (M) forms of human LDH’s have also been solved14.
Comparison between the P. falciparum and human LDH crystal structures
reveals a shift in the positioning of the NADH cofactor and a larger active
site14,42,95, the latter due to a five amino acid extension of the substrate-
binding loop42.
The problem of selective inhibition of LDH is compounded by the high levels
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of LDH present in the infected erythrocyte95, which requires high potency
inhibitors. Gossypol, a polyphenolic binaphthyl disequiterpene found in
cottonseed oil, has been shown to inhibit LDH’s at submicromolar (0.7 µM)
levels120. It binds competitively to NADH and displays anti-malarial activity
in vitro 56, with an IC50 of 10 µM14. Unfortunately, gossypol is cytotoxic.
Derivatives of gossypol have been synthesised in an attempt to decrease
toxicity, as well as maintain potency. Napthoic acid based compounds, such as
2,6-dicarboxy naphthalene, have been shown to span across the LDH active site
and NADH binding pocket14. The malarial and human LDH are very similar
and few unique properties exist, which makes selective targeting extremely
challenging. There are, however, significant kinetic differences between the
human and P. falciparum LDH14, which may be exploited.
2.5.1.15 Kinetic Parameters Present in Literature
The kinetic parameters that were obtained during the literature study are
summarised below in Table 2.1. Most of the glycolytic enzymes for Plasmodium
have been fully or partially characterised, although no kinetic parameters were
available for glyceraldehyde 3-phosphate dehydrogenase or phosphoglycerate
mutase.
2.5.2 Tricarboxylic Acid Cycle
"The tricarboxylic acid (TCA) cycle is the central wheel of mitochondrial
metabolism"153. The classical TCA cycle (Fig. 2.2.) occurs in aerobic
conditions and utilises acetyl-CoA, produced from glycolytic pyruvate. Acetyl-
CoA combines with oxaloacetate, to produce citrate. Citrate is broken down
by several steps that produce CO2, NADH, FADH2, GTP, and ultimately
oxaloacetate. NADH and FADH2 are used as electron donors in the electron
transport chain (ETC) to generate ATP. Experimentation and analysis of the
Plasmodium genome has revealed all the classical or equivalent TCA enzymes
(reviewed in153)
The existence or absence of a functional TCA cycle during the asexual stage
is still an area of discussion, although it is thought not to contribute much,
if at all, towards energy production during the asexual phase. Radioactive
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Table 2.1: Binding constants present in literature for Plasmodium spp.
Enzyme Metabolite Km (mM) Reference
Hexokinase Glucose 1 0.431 ATP 2.0 104,119
Phosphoglucoisomerase F6P 2 0.258 - 138
Phosphofructokinase F6P 0.032 ATP 0.720 19,18,17
Aldolase FBP 0.020 - 40
Triosephosphate Isomerase GAP 0.350 - 136
Glyceraldehyde 3 PDH - -
Phosphoglycerate Kinase ADP 0.300 BPG 0.0134 106,118
Phosphoglycerate Kinase ATP 0.630 3PGA 0.52 106,118
Phosphoglycerate Mutase - -
Enolase 2PGA 0.041 PEP 0.250 107
Pyruvate Kinase PEP 0.337 ADP 0.149 27
Lactate Dehydrogenase Pyr 0.030 NAD 0.086 56
Lactate Dehydrogenae Lac 12 NADH 0.007 56
Lactate Dehydrogenase Pyr 0.055 NAD 0.180 133
Lactate Dehydrogenase Lac 47 NADH 0.011 133
1 Binding constant determined from lysed Plasmodium-infected erythrocytes and
is a function of both Plasmodium and erythrocyte enzyme binding.
2 Average value of three isozymes shown. Standard deviation of the mean is 0.026
glucose, fed to P. falciparum infected erythrocytes, is converted predominantly
to lactate with minimal conversion to TCA intermediates8,21, which suggests
that the TCA cycle is not active during the erythrocyte stage of the parasite153.
Additionally, Plasmodium does not have a known accessible source of acetyl-
CoA for the TCA cycle. The formation of acetyl-CoA from pyruvate, in
most eukaryotes, is catalysed by pyruvate dehydrogenase (PDH) complex, a
large muti-enzyme complex localised in the mitochondrion. Plants possess
two distinct PDH complexes. One in a plastid, to supply acetyl-CoA for fatty
acid biosynthesis, the other in the mitochondrion to supply intermediates for
the TCA cycle50. P. falciparum, however, possesses only one PDH complex
located in the apicoplast50. The PDH complex in the apicoplast, prevents the
supply of acetyl-CoA to the TCA cycle and is thought to play a role in fatty
acid biosynthesis50. Furthermore, it appears that β-oxidation of fatty acids,
which produces acetyl-CoA, does not occur in Plasmodium 153. Percoll density
gradient and fluorescence -activated organelle sorting techniques were unable
to separate the apicoplast from the mitochondria leading to the suggestion
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Figure 2.2: Schematic representation of the classical tricarboxylic acid cycle. See
text for details.
that these organelles are physically connected81. If this is indeed the case,
it may be possible that acetyl-coA from the apicoplast is accessible to the
mitochondrion. In other organisms, acetyl-CoA may come from the catabolism
of amino acids, such as leucine and isoleucine, but not all the enzymes required
for this catabolic process are present in the genome of P. falciparum 153.
During the asexual stages of the parasite, the TCA cycle is possibly starved of
acetyl-CoA, which suggests that it does not play a role in energy metabolism.
During the erythrocyte stage this is highly likely, as the electron transport
chain has been shown to be essential for maintaining a mitochondrial
membrane potential, but not required as a source of ATP105.
An incomplete TCA cycle could, however, fulfill an anapleurotic function.
For example, glutamate can be converted to α-ketoglutarate, which in the
TCA cycle will yield NADH, two molecules of FADH2 and GTP. The active
degradation of the host cell by the parasite yields a vast supply of amino
acids, which could be channeled into the TCA cycle as a source of extra
energy or anapleurotic metabolites. The incomplete cycle would result in the
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accumulation of oxaloacetate, which would have to be transported out of the
mitochondrion, or diverted to biosynthetic processes153.
2.5.2.1 Mitochondria and Electron Transport Chain
A single mitochondrium is present during the entire Plasmodium life cycle
with the presence of cristae in avian malarial species, but obvious cristae are
lacking in mammalian Plasmodium parasites153. Plasmodium contains the
smallest mitochondrial genome ever reported at 6-kb, which encodes three
open reading frames149,47.
The function of the mitochondria during the sexual stages has not been
elucidated and the function during the asexual stages remains obscure, but
it does not contribute much to the cellular ATP pool52.
The Plasmodium ETC is similar to the classical ETC in many respects, as it
possesses homologues of complex III and IV153. Plasmodium does not possess
the usual rotenone-sensitive complex I, but instead has an alternative complex
I (type II NADH : dehydrogenase)54,10. Evidence for a complete F1F0ATP
Synthase is lacking, as only the five subunits of the F1 subunit have conserved
homologues in the P. falciparum genome153.
The major role of the electron transport chain appears to be an electron sink,
by regenerating ubiquinone, for the dihydroorotate dehydrogenase reaction in
the pyrimidine biosynthesis pathway. This was proven in an elegant manner
by Painter et al 105 who demonstrated that P. falciparum, expressing S.
cerevisiae dihidroorotate dehydrogenase (which does not require ubiquinone
as an electron acceptor) is completely resistant to ETC inhibitors.
The small mitochondrial genome would point towards the absence of many
classical mitchondrial functions. Plasmodium is exquisitely sensitive to
compounds removing the membrane potential105, but since mitochondrial ATP
production is not essential the importance of this membrane potential is not
known. It has, however, been proposed to be essential for cellular calcium
homoeostasis153.
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2.5.3 Pentose Phosphate Pathway
During the erythrocytic stages of the Plasmodium life cycle, the parasite is
engaged in intensive nucleotide synthesis and is subjected to endogenously
produced oxidative radicals12. The rapidly dividing parasitic cells require, in
addition to ATP, reducing power in the form of NAPDH12. NADPH is used
in a variety of important reactions, such as the conversion of ribonucleotides
to deoxyribonucleotides, catalysed by ribonucleotide reductase. The pentose
phosphate pathway (Fig. 2.1.) is essential for the production of nucleotides and
for the detoxification of the oxidative radicals. The detoxification mechanisms,
discussed later (Section 2.5.3.3: Link to Oxidative Defense), are largely
dependent on NADPH. The PPP serves to convert G6P to ribose-5-phosphate,
the latter being used by Plasmodium for nucleotide biosynthesis129,12. The
PPP is important for the production of NADPH, which serves as an electron
donor in reductive biosynthesis. The pathway can be divided into an oxidative
and non-oxidative branch:
2.5.3.1 Oxidative Branch
The oxidative branch is the first part of the pathway and utilises G6P as a sub-
strate. The oxidative branch produces two molecules of NADPH and ribulose-
5-phosphate. Isomerisation of the latter, by ribose phosphate isomerase
or ribulose-phosphate-3-epimerase, yields ribose-5-phosphate and xylulose-5-
phosphate, respectively. The classical branch consists of three enzymes:
glucose-6-phosphate-1-dehydrogenase (G6PD), 6-phosphogluconolactononase
(6PGL) and 6-phosphogluconate dehydrogenase12. In P. falciparum and
P. berghei, however, an enzyme with both 6-phosphogluconolactononase and
6-phosphogluconate dehydrogenase activity was discovered29. This finding
indicated the existence of a bifunctional G6PD-6PGL in Plasmodium 29.
2.5.3.2 Non-oxidative Branch
The non-oxidative branch of PPP is primarily for the production of 3,
5 and 7-carbon sugars, which may be used for biosynthetic purposes, or
channeled into glycolysis for energy production. The first step in the non-
oxidative branch, catalysed by transketolase, is the conjunction of ribose-
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5-phosphate and a 2-carbon fragment from xylulose-5-phosphate. This
reaction yields sedoheptulose-7-phosphate and GAP12. The second reaction
is catalysed by transaldolase and involves the transfer of three carbons
from sedoheptulose-7-phosphate to GAP, yielding erythrose-4-phosphate and
fructose-6-phosphate12. Transketolase catalyses a further reaction where an-
other molecule of xylulose-5-phosphate donates two carbon atoms to erythrose-
4-phosphate, yielding an additional molecule of GAP and F6P. Erythrose-4-
phosphate can be fed into the shikimate pathway12.
The purine salvage pathway, discussed later, can generate five-carbon sugars
(e.g. ribose-1-phosphate) and is linked to the PPP, since the sugars can be
converted to the glycolytic intermediates F6P and GAP12.
The flux through the PPP is dependent on enzyme expression and the cellular
NADPH/NADP+ ratio8. The reduced coenzyme NADPH inhibits G6PD-
6PGL, thus inhibiting the oxidative branch of the PPP. The PPP provides a
way to adapt to and supply the reductive and intermediate demands of the
parasite. During periods where the parasite requires both NADPH and ATP,
but not much R5P, the oxidative and non-oxidative branch run to completion,
with the resultant GAP and F6P being fed back into the glycolytic pathway.
When R5P is required in large quantities, the oxidative pathway is utilised and
F6P and GAP from the glycolytic pathway can be used to produce R5P12.
The non-oxidative pathway can function in reverse, utilising glyceraldhyde 3-
phosphate and F6P from the glycolytic pathway to produce ribose-5-phosphate
(R5P).
This has been shown to occur in P. falciparum by measuring incorporation of
[1-14C] glucose into nucleotides in G6PD deficient parasites5. It was reported
that 80% of the glucose incorporated into the nucleic acids comes from the
condensation of F6P and GAP.
A study based on metabolic labeling studies reported that P. falciparum
infected erythrocyte cells had a 78 fold increase in PPP activity, relative to
uninfected cells5. The parasites contributed 82% towards the PPP activity
and stimulated host activity, presumably in response to oxidative stress and
parasite burden.
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2.5.3.3 Link to the Oxidative Defense
The importance of the PPP in defence against reactive oxygen species
(ROS) is apparent when one has a look at the utilisation of NADPH in
the oxidative defence mechanisms. Degradation of haemoglobin provides the
parasite with amino acids and creates sufficient space for parasite growth9.
The degradation of haemoglobin in the acidic food vacuole produces toxic
free oxidised haem (ferri/ferroprotoporphyrin IX; FP) and ROS. The acidic
environment oxidises the FP in oxyhaemoglobin from the Fe (II) to Fe
(III) state, which "consequently results in the formation of superoxide that
dismutates spontaneously to H2O2 and O2"9. Both FP and H2O2 need to be
detoxified by the parasite. FP is detoxified by biomineralisation, a process
where FP is converted into a crystalline form, known as haemozoin9. It
is likely that some FP escapes crystallisation and diffuses into the parasite
cytoplasm129. It has been shown that FP can be present at 100 mM and
concentrations lower than this have been shown to inhibit parasite enzymes,
lyse erythrocytes and cause substantial redox damage9. It is thus essential for
the parasite to detoxify free FP.
Glutathione (GSH) and thioredoxin-dependent proteins play an integral role
in this detoxification. These proteins are oxidised by peroxides, the latter
being converted to H2O and O2. The oxidised proteins are reduced again
by NADPH, thus producing a continuous detoxification mechanism, provided
there is sufficient NADPH. The PPP is responsible for the reduction of NADP+
to NADPH, and is thus essential to the detoxification mechanism.
Despite the importance of the PPP for the survival of the parasite, research
aimed at inhibiting enzymes in the pathway is extremely limited. Compared to
the vast amount of information existing for the glycolytic pathway, structural
and kinetic data for the PPP is sparse, which may explain why researchers
have preferred to focusing on the inhibition of glycolytic enzymes.
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2.5.3.4 Pentose Phosphate Pathway Enzymes
2.5.3.5 Glucose-6-phosphate
dehydrogenase-6-phospho-glucono-lactonase
Early reports suggested that malaria parasites did not possess a G6PD and that
they depended on the host cell for NADPH. However, G6PD was found in P.
berghei and the parasite enzyme was found to account for 5% of the total G6DP
present in infected cells20. The same enzyme was discovered and purified from
P. falciparum 85,88. The G6PD gene has been cloned101,127. In its native form
the enzyme has an estimated molecular mass of 450 kDa129, which exists as
either a homodimer or homotetramer8. The gene of P. falciparum, which is
located on chromosome 14, suggests an estimated dimer size of 94 kDa, which
is striking, as it is almost twice as large as enzymes from other sources129.
The C-terminus has high homology to enzymes from other sources8, although
a segment of 62 amino acids shows no similarity. The N-terminal has an
additional 286129 to 31029 amino acid extension, rich in hydrophilic and
charged residues, compared to the human enzyme129. The N-terminal region
showed no homology to other G6PD enzymes, but was homologous to a
predicted protein encoded near to the G6PD in Haemophilus influenzae, which
suggested that it might encode a PPP enzyme18,126. The homologous human
cDNA was shown to encode for 6-phospho-glucono-lactonase activity32, which
led Clarke et al.29 to test for 6PGL. It was shown for P. berhei that the N-
terminal has 6PGL activity, while the C-terminal region has G6PD activity29.
G6PD-6PGL oxidises the first carbon of G6P to a lactone, which is linked to the
reduction of NADP+ to NADPH + H+. The resulting glucono-1, 5-lactone-6
is converted to 6-phospho-gluconate by the PGL activity of the N-terminal.
The 6-phospho-gluconate is decarboxylated and oxidised by G6PD, yielding
R5P, a molecule of CO2 and NADPH + H+.
Plasmodium have unique insertion sequences at the same genome position,
with varying sequence and size30. Excision of the insertions removed G6PD,
but not 6PGL activity. The function of the insertion is unknown, but is
suspected to play a structural role in the enzyme30. The insertion sequence
may be a potential drug target, since it is highly specific to the parasite.
Inhibition of G6PD-6PGL would prevent the production of NADPH and
should result in the parasite suffering from severe oxidative stress. The unique
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bifunctional enzyme G6PD-6PGL may allow the enzyme to be selectively
inhibited, with potentially excellent inhibitory effects on the parasite. The
resolving of a crystal structure of the bifunctional enzyme may reveal several
targets that offer specificity and selectivity.
2.5.3.6 6-Phosphogluconate dehydrogenase
This dehydrogenase catalyses the decarboxylation and oxidation of 6-phospho-
gluconate, yielding R5P, a molecule of CO2 and NADPH + H+. The activity of
6-phosphogluconate dehydrogenase has been detected indirectly and presumed
to be present in Plasmodium 49,143. The gene coding for the enzyme was
identified in P. falciparum 12, but further information about the enzyme is
limited.
2.5.3.7 Transketolase
Transketolase catalyses a reaction where xyulose-5-phosphate donates 2 carbon
atoms to erythrose-4-phosphate, yielding GAP and F6P. The gene coding for
transketolase, has been identified in P. falciparum 12 and the enzyme has has
been expressend, localised and biochemically characterised in P. falciparum 72.
2.5.3.8 Transaldolase
The transaldolase reaction involves the transfer of 3 carbons from sedoheptulose-
7-phosphate to GAP, yielding erythrose-4-phosphate and F6P. Surprisingly,
the gene that codes for transaldolase could not be found in the genome of any
Plasmodium species, or in any Apicomplexans, although biochemical evidence
suggests the presence of a functional non-oxidative branch12. It may be
possible that a novel enzyme performs the same function.
2.5.3.9 Ribose phosphate isomerase
Ribose phosphate isomerase catalyses the interconversion of ribose 5-phosphate
and ribulose 5-phosphate. The genes coding for ribose phosphate isomerase
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have been identified in P. falciparum 12. The crystal structure has recently been
determined63, but no research has been directed at kinetically characterising
the enzyme.
2.5.3.10 Ribulose-phosphate 3-epimerase
Ribulose-phosphate-3-epimerase catalyses the isomerisation of ribulose-5-
phosphate, yielding xylulose-5-phosphate. The gene coding for ribulose-
phosphate 3-epimerase has been identified in P. falciparum 12. Recently the
crystal structure of P. falciparum ribulose-phosphate 3-epimerase was resolved
to 2 Å24. The structure is a classic TIM-barrel fold, with a coordinated Zn2+
ion and a bound sulfate ion in the active site24.
2.5.4 Ancillary pathways
The malarial parasite has several supplementary pathways, such as purine
salvage pathways and carbon dioxide fixation. The latter supplies free amino
acids, keto acids and organic acids to the parasite.
2.5.4.1 Carbon dioxide fixation
All the malarial parasites studied are capable of fixing CO2 129 (Fig. 2.1.) ,
which is extremely interesting. The exact role of the fixation is not known,
but it is indispensable to the parasite129.
Intra-erythrocyte P. falciparum is capable of fixing carbon dioxide, but the
contribution of carboxylation towards the utilisation of glucose and ATP yield
is unclear59. Both phosphoenolpyruvate (PEP) carboxylase and PEP carboxy
kinase (PEPCK) are present in P. berghei 137. PEP carboxylase has been
isolated and characterised from P. berghei 94. The PEP carboxylase appears
to be unique to P. berghei, and is not present in other Plasmodium species.
PEP carboxylase catalyses the carboxylation of PEP to oxaloacetate. PEPCK
is capable of reversible carbon dioxide fixation and is found in mammalian cells,
protozoa and plants59. PEPCK catalyses the carboxylation of PEP, to yield
oxaloacetate and ATP59. Carbon dioxide appears essential for parasite growth
and survival59. The rate at which carbon dioxide is fixed, and the capacity of
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carbon dioxide fixation is not known.
It was shown that 14C-labeled bicarbonate was incorporated into certain amino
acids and organic acids130. Fixation in P. lophurae and P. knowlesi has
been shown to contribute to pyrimidine synthesis, metabolic products, free
amino acids, keto acids and organic acids130,131,145. The ability to fixate
carbon dioxide reduces the dependency on the host cell for intermediates,
thus resulting in a more resilient parasite. It would be interesting to quantify
the effect of carboxylase inhibition. Cellular carbon dioxide is derived from
bicarbonate. Bicarbonate anhydrase catalyses the reversible hydration of
carbon dioxide [CO2 + H2O ↔ HCO−3 + H+]83,114. The de novo synthesis
of pyrimidine requires HCO−3 , which can be provided by carbonic anhydrase.
Bicarbonate anhydrase may also play a role in the transport of bicarbonate
into the erythrocyte53, as well in the regulation of intracellular pH132. It would
thus appear that the enzyme is essential and linked to carbon dioxide fixation.
The human erythrocyte has two isozymes (I & II) of carbonic anhydrase
and three isozymes have been identified in P. falciparum 83. Due to high
levels of both host and parasite carbonic anhydrase during the erythrocyte
phase, inhibition of the parasite enzyme would be expected to inhibit the
host enzyme as well. It was shown that the human and parasite enzymes
have different inhibition constants (Ki) for acetazolamide (99 nM and 247
nM, respectively) and sulfanilamide (145 µM and 56 µM, respectively)114.
Derivatives of sulfanilamide may result in a more potent inhibition of the
malarial enzyme, whilst leaving the host enzyme relatively unscathed.
The fixation pathway and the enzymes responsible need to be better studied
in order to evaluate the possibility of using the pathways in drug development.
2.6 Summary
This review has covered malaria history, treatment and asexual carbohydrate
metabolism.
The parasite utilises glucose from the host serum as an energy source.
Energy is obtained predominantly by anaerobic glycolysis, with the subsequent
production of lactate. Buildup of lactate is prevented by rapidly transporting
the acid from the erythrocyte by anion-selective diffusion pathways and a
lactate-proton cotransporter.
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Since the predominant ATP supply in Plasmodium is glycolysis, the pathway
has great potential as a drug target. Aldolase, TIM and LDH have been
crystallised revealing areas that may be used for drug design. Although these
enzymes in isolation have been proposed as drug targets, the pathway as a
whole has not been considered. Construction and analysis of a kinetic model of
the glycolytic pathway would allow researchers to gain a better understanding
of the pathway in its entirety and identify enzymes which control the majority
of the flux.
The exact function of the TCA cycle, during the asexual phases, and its
importance to the parasite is not known, but it is unlikely to play a major
role in ATP production. A plausible hypothesis is presence of an incomplete
cycle, which utilises amino acids for anapleurotic functions.
The ETC differs slightly from the classical ETC, as it has an alternative
complex I and lacks an complete F1F0ATP synthase. The ETC has been
proposed to act as an electron sink and may play a role in calcium homeostasis.
The PPP was shown to be extremely important for the oxidative defence
mechanism, as it supplies the necessary NADPH for the defence system. The
PPP may also function in reverse, converting purines scavenged from the
host erythrocyte, to the glycolytic intermediates F6P and GAP. Despite the
importance of the PPP to parasite survival, it has not been suggested as a
drug target. The novel bifunctional enzyme, G6PD-6PGL, which is essential
for the reduction of NADP in the oxidative branch, may prove to be a novel
drug target. The enzyme should have several structural differences compared
to the separate enzymes, which may provide excellent drug selectivity. Before
this avenue could be explored, however, structural features of the bifunctional
enzyme would have to be determined.
The peculiar carbon dioxide fixation pathways are essential to the parasite and
have been shown to contribute to pyrimidine synthesis, metabolic products,
free amino acids, keto acids and organic acids. Further study of the enzymes
responsible for the fixation may uncover novel drug targets.
Although membrane structures of the parasites have not been discussed, it
has to be mentioned that designing a drug to bind to a specific target in
Plasmodium is only the beginning of a cure. Delivery of the drug to the
target is extremely difficult, as the parasite has its own membrane within the
erythrocyte. Drugs, therefore, not only have to selectively inhibit the target
enzyme, but must also be able to cross both host and parasite membranes.
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The wide range of possible drug targets impedes the rapid development of
drugs, as many prove to be inappropriate or ineffective. A systems biology
approach to the metabolism may identify the more essential enzymes. Control
analysis of the metabolic pathways, can be used to pinpoint the most important
regulatory enzymes in a pathway. The enzymes of the glycolytic pathway
have nearly all been kinetically characterised, which presents an attractive
opportunity to use a systems biology approach and identify the most important
regulatory enzymes. Identification of these enzymes may fast track the
development of an antidote.
The life cycle of the malarial parasite, its interactions with its host and
its metabolism is extremely complex. Unraveling the detail of Plasmodium
presents a significant challenge, which has to be overcome in order to find new
cures for this endemic parasite. The carbohydrate metabolism as a drug target
definitely has potential, but much research is required. A global, concerted
effort will greatly aid the discovery of effective and selective drugs.
Chapter 3
Methods
3.1 General Overview
The aim of the project was to construct a kinetic model of glycolysis for the
the asexual (trophozoite stage) P. falciparum. As such, Plasmodium had to be
cultured, trophozoites isolated from the erythrocyte and the glycolytic enzymes
kinetically characterised from parasite lysates. Additionally, validation data in
the form of glycolytic fluxes and intermediate metabolites had to be determined
in whole trophozoites. All intermediates, enzymes and reagents were obtained
from Sigma (Steinheim, Germany), except in the case of Albumax II and
RPMI-1640 (Scientific Group in Auckland, New Zealand) and G6P, F6P, 3PGA
and 2PGA (Boehringer in Ingelheim, Germany ).
3.2 Culturing of Plasmodium falciparum D10
Packed human erythrocytes (A+) were infected with Plasmodium falciparum
D10 and cultured in RPMI 1640 culture medium supplemented with Albumax
II36,146. Cultures were incubated with 3% oxygen, 4% carbon dioxide and 93%
nitrogen at 37 ◦C
Incomplete culture medium was prepared as described previously36 by sup-
plementing RPMI 1640 with Albumax II(R) (0.5% m/v), glucose (22mM),
HEPES (25mM), hypoxanthine (3mM) and gentamycin sulphate (50µg/mL).
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The medium was sterilised by filtration (0.2µM) and stored at 4◦C for up to 2
months. Before use, the medium was completed by adding filter sterilised 5%
sodium bicarbonate to a final concentration of 25mM. The complete medium
was used within two weeks.
Synchronisation of parasites was achieved by centrifuging infected erythrocytes
(750 × g, 3min), suspending the pellet in 5% sorbitol solution and incubating
the suspension at 37◦C for 5 min66. Following further centrifugation (750 ×
g, 3min) and aspiration of the supernatant, the infected erythrocyte pellet was
resuspended in culture media and placed into culture flasks. Sorbitol destroys
all but ring stage parasites, thus keeping cultures in a specific phase.
3.3 Trophozoite Isolation
This project used parasites in the mature trophozoite-phase (36-40 hours
post erythrocyte invasion). The trophozoites were freed from the erythrocyte
using a saponin lysis protocol123. Saponin permeabilises the erythrocyte and
parasitophorous vacuolar membranes by interacting with cholesterol found
in these membranes3,4, but leaves the parasite plasma membrane intact and
able to maintain a transmembrane ion gradient and a substantial membrane
potential123,122 with greater than 95% of parasites isolated in this manner
maintain the ability to exclude 0.04% trypan blue121.
Saponin with a final concentration of 0.05% w/v and 0.005% active component
sapogenin was added to infected erythrocytes suspended in culture medium
(5% hematocrit). Upon addition of saponin, the suspension was rapidly mixed
by inversion and then centrifuged for 6 minutes at 1800 × g. The supernatant
was removed and the parasites were resuspended in culture medium and
washed twice more in a buffer identical to that used in the applicable assay.
Trophozoites isolated in this manner were used within an hour of isolation or
stored at -80◦C for later use. The supernatant from the final wash was retained
as a control and tested for the presence of contaminating erythrocyte enzymes.
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3.4 Kinetic Parameter Determination
The literature review yielded kinetic parameters for a large number of
glycolytic enzymes (Literature review: Section 2.5.1 Table 2.1). Unfortunately,
many of these enzymes were characterised at optimal conditions or in different
species or strains of Plasmodium, which may yield kinetic parameters that
differ significantly from those determined under physiological conditions or
P. falciparum D10, respectively. Parameters were therefore determined for
most of the glycolytic enzymes under physiological conditions. In cases where
the parameters were not determined, they were obtained from literature.
Characterisation of the asexual Plasmodium glycolytic enzymes was performed
using trophozoite lysates.
3.4.1 Enzyme Assays
Each glycolytic enzyme was kinetically charaterised in terms of its affinity
to each substrate and product, as well as it maximal rate. The assays used
for the characterisation of the glycolytic enzymes were adapted from Teusink
et al 142. Isolated trophozoites were suspended in an assay buffer containing
HEPES (20 mM), MgCl (20 mM), K2HPO4 (1 mM), KCl (10 mM) and NaCl
(20 mM). The high magnesium concentration was used to ensure that ATP
was predominantly in the active MgATP form. The pH was set to 7.17 to
match the cytosolic pH of P. falciparum D10 163. It is interesting to note that
the cytosolic pH differs substantially between species and strains, especially
in those that are chloroquine resistant163. Isolated trophozoites were lysed by
using three freeze-thaw cycles. Trophozoites were frozen in liquid nitrogen and
thawed on ice. The lysis protocol was optimised by the inclusion of a 30 second
sonication step between freeze-thaw cycles. The supernatant was retained and
used for kinetic determinations after a 10 minute 10 000 ×g centrifugation
step.
The enzyme rates were determined using enzyme/NADH/NAD/NADP linked
reactions, which were be measured at 340nm in 96 well plates (Greiner bio-
one Flat Bottom microplate) on a spectrophotometer (VarioSkan microplate
reader, Thermo Electron Corporation ). For uni-substrate reactions, the
substrate concentration was varied. For bi-substrate reactions the rate
was determined by varying one substrate concentration whilst maintaining
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saturating concentrations of the other substrate. All reagents and enzyme
dilutions were made up in the assay buffer described previously.
To ensure that observed enzyme activity was Plasmodium enzyme specific the
supernatant from the final trophozoite isolate wash was retained and tested
for contaminating erythrocyte enzyme activity. This contained negligibly low
LDH activity, when compared to the lysate activity. Before substrate was
added to commence the assay, activity was measured to ensure no residual
substrate or oxidase activity (oxidising NADH/NADPH) was present. The
use of excess enzymes in the assay also ensured that only the activity of the
enzyme being characterised was limiting the overall reaction.
3.4.1.1 Hexokinase
Forward reaction: The rate of glucose phosphorylation was measured by
linking the hexokinase reaction to NADP/G6PDH and measuring the accu-
mulation of NADPH at 340 nm. Glucose was added to wells containing ATP,
assay buffer, G6PDH (3U/ml), NADP (0.2mM) and lysate.
Inhibition by G6P : Inhibition of HK by G6P (1 mM) was assayed under
saturating concentrations of ATP and glucose by linking the reaction to α-
glycerolPDH (4U/ml) and NADH (0.2 mM), via PFK (5U/ml), TPI (5 U/ml)
and PGI (20 U/ml)
3.4.1.2 Phosphoglucoisomerase
Forward reaction: The rate of G6P isomerisation was determined by linking
the reaction to α-glycerolPDH (4 U/ml) and NADH (0.2 mM) in the presence
of excess PFK (12.5 U/ml), TPI (5 U/ml), ALD (4 U/ml) and ATP (1 mM).
Reverse reaction: The conversion rate of F6P to G6P was measured by linking
the reaction to G6PDH (3 U/ml) and NADP (0.2 mM).
3.4.1.3 Phosphofructokinase
Forward reaction: The phosphorylation rate of F6P by ATP was measured by
linking the reaction to α-glycerolPDH (4U/ml) in the presence of excess ALD
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(4U/ml), TPI (5U/ml) and NADH (0.2 mM).
Reverse Reaction: The reverse rate could not be measured reproducibly by
linking the reaction to G6PDH (3U/ml) and NADP (0.2 mM), via PGI (20
U/ml).
3.4.1.4 Aldolase
Forward reaction: The rate of aldol cleavage of F 1,6BP was measured by
linking the reaction to α-glycerolPDH in the presence of NADH (0.2mM),
TPI (5U/ml) and GlycerolPDH (4U/ml).
Reverse reaction The reverse rate in the presence of excess GAP and DHAP
could not be measured by linking the reaction to G6PDH (3 U/ml) and NADP
(0.2 mM) via ALD (4 U/ml), TPI (5U/ml), PFK (5 U/ml) and PGI (20 U/ml).
This is presumed to be due to PFK, which is not very reversible.
3.4.1.5 Triosephosphate Isomerase
Forward reaction: The conversion rate of GAP to DHAP was measured by
linking the reaction to α-glycerolPDH (4U/ml) and NADH (0.2 mM).
Reverse reaction: The conversion rate of DHAP to GAP was measured by
linking the reaction to G3PDH (10U/ml) and NAD (0.2 mM) in the presence
of PGK (50U/ml) and ADP (1 mM) to remove the accumulation of product.
The measured rates did not, however, yield a rate that was proportional to
substrate concentration.
3.4.1.6 Glyceraldehyde 3 Phosphate Dehydrogenase
Forward reaction: The conversion rate of GAP and NAD to 1,3 BPG and
NADH was determined in the presence of PGK (50U/ml) and ADP (1 mM),
but did not yield a rate that was proportional to substrate concentration.
Reverse reaction: The G3PDH reaction rate was determined by measuring the
decrease in NADH concentration as 1, 3 BPG is converted to GAP with the
formation of NAD. Since 1,3 BPG is chemically unstable, 3PGA is used in the
presence of excess PGK (50U/ml) and ATP (1mM) to provide the substrate 1,
3 BPG. This method is based on the assumption that all 3PGA is converted
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to 1, 3 BPG and a negligible amount is converted to 2PGA by PGM. The
rapid rate of PGM, however, would result in an apparent Km that is lower
than the actual Km. The Vmax is not expected to be affected, as it is based
on a saturating substrate concentration.
3.4.1.7 Phosphoglycerate Kinase
Forward reaction: The dephosphorylation of 1,3 BPG to 3PGA could not be
measured, since 1,3 BPG is chemically unstable.
Reverse reaction: The rate of 3PGA phosphorylation was determined by
linking the reaction to G3PDH (10 U/ml) in the presence of NADH (0.2 mM)
and measuring the decrease in absorbance at 340 nm.
3.4.1.8 Phosphoglycerate Mutase
Forward reaction: The mutase reaction was linked to LDH (5 U/ml), via PK
( 10 U/ml) in the presence of ADP (1 mM) and NADH (0.2 mM).
Reverse reaction: The conversion of 2PGA to 3PGA was measured by linking
the reaction to G3PDH (10 U/ml) via PGK (5 U/ml) in the presence of ATP
(1 mM) and NADH (0.2 mM).
3.4.1.9 Enolase
Forward reaction: The rate of 2PGA conversion to PEP was measured by
linking the reaction to LDH (5U/ml) and NADH (0.2 mM) in the presence of
excess PK (10 U/ml) and ADP (1 mM)
Reverse reaction: The reverse reaction was linked to G3PDH (10 U/ml) in
the presence of NADH (0.2 mM, excess PGM (10 U/ml), PGK (50 U/ml) and
ATP (1 mM).
3.4.1.10 Pyruvate Kinase
Forward reaction: The rate of PEP and ADP utilisation was determined by
linking the reaction to LDH (5 U/ml) and NADH (0.2mM).
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Reverse reaction: The reverse reaction could not be determined reproducibly
by linking the reaction to G3PDH.
3.4.1.11 Lactate Dehydrogenase
The rate of substrate or product utilisation was determined by measuring the
amount NADH/NAD utilised with time in each reaction, respectively.
3.4.2 Binding Constant Determination
The initial maximum reaction rates were determined over a minimum period
of 30 seconds for each different substrate/product concentration by using
the linear slope (R2 > 0.90) and the extinction coefficient for NADH (6.22
mM−1.cm−1). The pathlength in the Greiner bio-one 96 well plate was
determined by using the following equation:
pathlength = 465.6(0.01808 + 0.00001384 · volume) 13 − 122.2
Where, the pathlength (mm) is given as a function of working volume (µL).
The derivation for this equation can be found in Appendix A. The pathlength
for the typical 100µL assay working volume was calculated to be 3.0419 mm.
By plotting the substrate concentration versus the corresponding maximal
rates (normalised to protein concentration), a nonlinear curve was typically
obtained. Nonlinear regression of these data, using the irreversible Michaelis-
Menten equation, yielded binding and Vmax constants.
It is expected that glycolytic enzyme expression levels vary between Plasmod-
ium cultures and isolations, which would alter the Vmax values as they are a
function enzyme concentration and a catalytic rate constant. To counter this
problem a homogenate of many trophozoite isolates was prepared and used to
determined all the Vmax values, under saturating conditions. Regression was
performed using Wolfram Mathematica 6.0, which also provides the statistics
of the fits.
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3.5 Model Construction
Using the parameter values determined for each enzyme and standard kinetic
equations, a kinetic model was constructed in Wolfram Mathematica 6.0. In
the model, glucose is entirely converted to lactate with the assumption that
flux through the pentose phosphate pathway and carbon dioxide fixation is
negligible when compared to the glycolytic flux. This assumption is supported
by observations that one mol glucose produces two moles lactate and two moles
ATP129.
In instances, where parameters could not be determined experimentally or
obtained from literature, they were fitted or estimated. Estimation was
achieved by comparing the kinetic parameters obtained in different organisms
and obtaining an average. This approach is based on the assumption that
enzymes active sites are conserved and that binding constants would not
change by more than an order of magnitude.
The model consists of a set of ordinary differential equations, which describe
the change in metabolite concentration over time as a function of enzyme
rates. The rate of each each enzyme is described using various rate equations
(e.g reversible and irreversible uni-substrate Michaelis-Menten or bi-substrate
generic116, Monod-Wyman-Changreux and Ping-Pong Bi-Bi equations).
3.6 Validation Data: Fluxes and Intermediate
Metabolite Concentrations
An important part of kinetic modeling is model validation. The model
in this study was constructed using parameters and equations for enzymes
that had been characterised in isolation. Steady state analysis of the model
provides metabolite concentrations and fluxes, which are predictions of the
system working together as a whole. This provides a suitable means of
validation since it is possible to experimentally determine steady state fluxes
and intermediate concentrations. The validation data is thus also independent
of model construction data.
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3.6.1 Glucose Uptake and Lactate Production Incubations
In order to determine the glycolytic flux and intermediate metabolite con-
centrations, isolated trophozoites were washed and incubated in a modified
culture medium, which contained RPMI 1640, hypoxanthine (3mM), glucose
(10mM), HEPES (25mM) and the pH adjusted to 7.1 to mimic the pH found
within the erythrocyte123. The trophozoite suspension (approximately 1 - 10
×107 cells/ml) was incubated in a water bath at 37 ◦C for up to 8 hours. At
specific time points 200 µL samples of the trophozoite suspension were added
to 50 µL PCA ((6% final concentration), immediately placed in liquid nitrogen
and stored at -80 ◦C until further use. Following thawing and neutralisation
with 1 M sodium hydroxide, the samples were centrifuged at 10 000 ×g at
4◦C for 10 min and the supernatant used for glucose, lactate and internal
intermediate metabolite concentrations. Before incubation, the trophozoites
were counted and checked for membrane integrity by suspending the cells in
0.04% Trypan blue and visualising them in an improved Nebauer counting
chamber. Typically 85 - 95 % of the trophozoites were able to exclude trypan
blue.
3.6.2 Glucose and Lactate Assays
Extracellular glucose was assayed using a HK, G6PDH, NADP linked assay.
Samples and standards were incubated in a triethanolamine buffer pH 8.6
containing HK (10 U/mL), ATP (0.2 mM), G6PDH (10 U/mL) and NADP
(0.5 mM). After a 15 minute incubation period the absorbance at 340 nm was
measured. A standard curve in the range of (0-20mM) was constructed and
used to determine glucose concentrations present in the samples.
Extracellular L-lactate was assayed using a LDH, NAD+ linked assay. Samples
and standards were read at 340 nm after being incubated for 20 min at room
temperature in HEPES buffer (20 mM) containing LDH (10 U/ml), NAD+
(0.2 mM) and hydrazine (16 µL/ml). Hydrazine is used since it binds to
pyruvate and thus thermodynamically drives the unfavourable LDH reaction
(reverse) to completion. A calibration curve in the range of 0-20 mM lactate
was constructed.
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3.6.3 Protein determination
Protein concentrations for the incubations or enzyme assays were performed
on lysates. In the case of whole cell incubations, the cells were lysed before
protein determination. Protein concentration was determined by using the
method of Bradford13. The protocol was adapted for use in 96 well plates,
where 180 µL of Bradford reagent was added to 5 µL of sample or standard
and incubated for 15 minutes followed by reading the absorbance at 595 nm.
As a standard, a BSA calibration curve in the range of 0 - 1 mg/mL was
utilised.
Chapter 4
Experimental Results and
Discussion
This chapter covers the experimental aspects of this work, which includes
the kinetic characterisation of the glycolytic enzymes, the determination of
glycolytic flux and the establishment of a protocol to measure glycolytic
intermediate concentrations. These results are employed for the construction
and partial validation of a kinetic model in the upcoming theoretical results
chapter (Chapter 5).
4.1 Enzyme Characterisation
Most of the P. falciparum glycolytic enzymes were kinetically characterised
using trophozoite lysates. In the following section the kinetic parameters (Km,
Vmax, Keq) as well as the rate equation obtained for each enzymatic reaction
are presented.
It should be noted that the Km values were determined from separate
trophozoite isolates and were shown not to differ significantly (p < 0.1) between
different isolations. The Vmax values, however, were all determined from a
single homogenate, consisting of several isolates, and are thus representative
of an average expression level during the trophozoite stage. This approach was
utilised, since it has been shown that glycolytic enzyme expression levels (and
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thus Vmax) vary during the asexual stage23.
Equilibrium constants for each of the enzymatic reactions were obtained by
searching the Goldberg database55, which contains numerous thermodynamic
parameters and specifies the conditions under which they were determined.
Equilibrium constants which had been determined under conditions similar to
those used in this study were chosen.
In instances, where only the reverse Vmax could be determined, the uni-
or bi-substrate Haldane relationship (Eqns. 4.1.1 and 4.1.2 respectively),
which describes the relation between maximal rates, binding and equilibrium
constants, was used to determine the forward Vmax or vice versa. Additionally,
in instances where both the forward and reverse rates were determined, the
Haldane relationship was used to determine an apparent Keq. Comparison of
this estimated equilibrium constant to values available in literature gives an
indication of how accurate the kinetic parameters as a whole are.
Vforward =
Vreverse ·Ksubstrate ·Keq
Kproduct
(4.1.1)
Vforward =
Vreverse ·Ksubstrate1 ·Ksubstrate2 ·Keq
Kproduct1 ·Kproduct2 (4.1.2)
Where, Vforward and Vreverse are the maximal forward and reverse rates,
respectively, Ksubstrate and Kproduct are the affinities of substrate and product
for the enzyme and Keq is the equilibrium constant of the reaction.
In the following subsections, the rate equations derived for each glycolytic step
are presented with the parameters values that were obtained for the equation.
4.1.1 Glucose Transporter
P. falciparum possesses a single glucose and fructose transporter, PfHT1. A
recombinant PfHT1 has been characterised in frog oocytes71.
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Although the transporter was not characterised in this study, it was assumed
to follow reversible Michaelis-Menten kinetics (Eq. 4.1.3) and bind internal
and external glucose symmetrically. Kinetic parameters that were used for the
rate eqaution are displayed in Table 4.1.
Since the expression levels of the transporter in P. falciparum during the
asexual phase are not known a range of Vmax values (Table 4.1.) were used
for the kinetic model simulations (see Section 5.2.).
vGlcTr =
(Vf · glcex(1− glcintglcex·Keq )
Kmglcex(1 +
glcex
Kmglcex
+ glcintKmglcint
)
(4.1.3)
Where vGlcTr is the glucose transporter rate, Vf is the maximal forward
reaction rate, glcint is the internal parasite glucose concentration, glcex is
the external parasite glucose concentration, Kmglcex is the affinity of external
glucose to the transporter, Kmglcint is the affinity of the internal glucose to the
transporter and Keq is the equilibrium constant of the reaction.
Table 4.1: Kinetic parameters for the P. falciparum hexose transporter.
Metabolite Km(mM) Reference
Glucoseexternal 0.97 ± 0.34 71
Glucoseinternal 0.97 1
Equation Parameters
Vmax(forward) 0.01-0.12
2 µmol.min−1.mg protein−1
Keq 1.0
1 Assumed symmetrical binding.
2 Range of Vmax values there were used during model simulations.
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4.1.2 Hexokinase
Hexokinase was assumed to be product insensitive and was described by the
an irreversible Michaelis-Menten rate equation (Eq 4.1.4.). The enzyme was
characterised in terms of its substrates, Glucose and ATP (Fig. 4.1).
vHK =
Vf · glcint · atp
Kmglcint ·Kmatp(1 + glcintKmglcint )(1 +
atp
Kmatp
)
(4.1.4)
Where vHK is the reaction rate, Vf is the maximal forward rate, glcint is the
internal glucose concentration, atp is the ATP concentration, Kmglcint is the
affinity of internal glucose for hexokinase and Kmatp is the affinity of ATP for
hexokinase.
The affinities of the enzyme were calculated, using nonlinear regression of
the data shown in Fig 4.1 A & B using the above rate equation (Eq. 4.1.4.),
to be 0.14 and 0.57 mM for glucose and ATP, respectively (Table 4.2.).
These values are approximately four fold smaller than when previously
determined119. This discrepancy may be due to the fact that previous
determinations (Table 4.2.) were done at a higher pH (7.4) using lysed P.
falciparum infected erythrocytes (enriched to 60% parasitemia) and thus the
apparent Km estimations are a function of both parasite and erythrocyte
enzymes binding. Differences in the Vmax values under saturating glucose
or ATP conditions are a result of different parasite isolations being used for
the respective assays.
Table 4.2: Kinetic parameters for P. falciparum hexokinase determined previously
and in this work.
Metabolite Km(mM) Reference Km(mM) Reference
Glucoseinternal 0.14 ± 0.017 This work 0.431 ± 0.021 119
ATP 0.57 ± 0.06 This work 3.1 ± 1.4 119
Equation Parameters
Vmax(forward) 0.325 ± 0.0092 µmol.min−1.mg protein−1 This work
Chapter 4. Experimental Results and Discussion 52
A
0 2 4 6 8 10
0.00
0.05
0.10
0.15
Glucose HmML
R
ea
ct
io
n
R
at
e
Hm
m
o
lm
in
m
g
pr
ot
ei
nL
B
0.0 0.5 1.0 1.5 2.0 2.5 3.0 3.5
0.00
0.02
0.04
0.06
0.08
0.10
ATP HmML
R
ea
ct
io
n
R
at
e
Hm
m
o
lm
in
m
g
pr
ot
ei
nL
Figure 4.1: Kinetic characterisation of P. falciparum hexokinase in terms of
its substrates. A) Glucose was varied between 0-25 mM, at saturating ATP
concentrations (5 mM) and B) ATP was varied between 0-3.5 mM, at saturating
glucose concentrations (10 mM). Fitting with the Michaelis-Menten equation
(shown) was used to determine Vmax and Km values. Error bars represent standard
deviation of the mean (n = 3).
Hexokinase was found to be insensitive to low concentrations (1mM) of G6P
(results not shown). Kinetic model predictions of the G6P concentrations as
steady state (see Chapter 5.2), however, are higher than 10 mM and it may be
that hexokinase is inhibited by higher concentrations of G6P. Assays, which
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will measure product sensitivity over a wider range of product concentrations
will be performed to determine if the product insensitivity assumption is valid.
4.1.3 Phosphoglucoisomerase
PGI was characterised in term of its substrate and product (Fig. 4.2.) and
was described using a reversible Michaelis-Menten equation (Eq. 4.1.5.).
vPGI =
Vf · g6p(1− f6pg6p·Keq )
(Kmg6p(1 + g6pKmg6p +
f6p
Kmf6p
)
(4.1.5)
Where vPGI is the reaction rate, Vf is the maximal forward rate, g6p is the
internal G6P concentration, f6p is the F6P concentration, Kmg6p is the affinity
of G6P for PGI and Kmf6p is the affinity of F6P for PGI.
Parameters obtained for PGI are presented in Table 4.3. The apparent Keq
for the reaction, 0.138 as obtained using the haldane relationship (Eq. 4.1.1.),
is the in the same order of magnitude as that present in literature, 0.330. The
Km determined previously by Srivastava et al 138 is approximately three times
higher than determined in this work (Table 4.3), but the discrepancy may
be due to the use of a different P. falciparum strain (M25) or different assay
conditions (pH 8.0).
Table 4.3: Kinetic parameters obtained for P. falciparum phosphoglucoisomerase.
Metabolite Km(mM) Reference Km(mM) Reference
G6P 0.92 ± 0.098 This work
F6P 0.081 ± 0.0034 This work 0.258 ± 0.0261 138
Equation Parameters
Vmax(forward) 0.363 ± 0.0326 µmol.min−1.mg protein−1 This work
Vmax(reverse) 0.232 ± 0.0354 µmol.min−1.mg protein−1 This work
Keq 0.330 139 0.1382 This work
1 Average value of three isozymes with standard deviation of the mean
shown.
2 Apparent Keq estimated using the Haldane relationship. (See Section
4.1 for details.
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Figure 4.2: P. falciparum phosphoglucoisomerase was characterised in terms of
A) its substrate, glucose 6-phosphate, and B) its product, fructose 6-phosphate.
A) Fitting (shown) of the data to a Michaelis-Menten equation was used to procure
Vmax and Km values. Error bars represent standard deviation of the mean (n =
3).
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4.1.4 Phosphofructokinase
PFK has been extensively characterised previously in terms of allosteric
regulation and have not yet been repeated in this study, but will form part of
future studies. The reaction was described by a Monod-Wyman-Changeux rate
equation (Eq. 4.1.6.) and the corresponding parameter values are presented
in Table 4.4.
vPFK =
Vf · atp · f6p
(atp+Katp(1 + adpKadp ))(f6p+Kf6p)
(
1
1 + Lo
)
Lo = L(
(1 + MgKmg )(1 +
atp
Katp
)
(1 + f6pKf6p2 )(1 +
pep
Kpep
)
)n (4.1.6)
Where vPFK is the reaction rate, Vf is the maximal forward rate, atp, f6p,
Mg, adp, pep are the ATP, F6P and Mg2+, ADP and PEP concentrations,
Kadp, Kf6p are Michaelis constants for ADP and F6P, Katp, Kmg are inhibition
constants for ATP and Mg2+, Kf6p2, Kpep are activation constants for F6P
and PEP, L is the equilibrium constant for the transition between the R and
T state and n, is the number of subunits.
Table 4.4: Kinetic parameters obtained predominantly from literature, which were
used for the description of phosphofructokinase kinetics.
Metabolite Km(mM) Reference
F6P 0.034 17
F6P2 0.054 17
ADP 0.17 17
ATP 0.028 17
Mg2+ 0.78 17
PEP 0.13 17
Equation Parameters
Vmax(forward) 0.142 ± 0.0167 µmol.min−1.mg protein−1 This work
Mg2+ 0.5 mM Assumed
n 3.92 17
L 3.22 17
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The forward and reverse maximal enzyme rates were determined using
substrate and product concentrations ten times greater than the respective
Km values under high magnesium concentrations. Since magnesium is not
explicitly modeled in any of the other reactions and that all ATP is assumed to
be in the active magnesium bound form, the concentration of free magnesium
was fixed at 0.5 mM.
4.1.5 Aldolase
Aldolase was characterised in terms of its substrate, F1,6DP (Fig. 4.3.). The
reaction was described using a reversible random order rapid equilibrium rate
equation (Eq. 4.1.7.).
vALD =
Vf · f16bp(1− dhap·gapf16dp·Keq )
Kmf16dp(1 +
f16bp
Kmf16dp
+ dhapKmdhap +
gap
Kmgap
+ gap·dhapKmgap·Kmdhap )
(4.1.7)
The substrate (F1,6DP) affinity determined in this work ( Table 4.5.) was
in the same order of magnitude as determined by Dobeli et al 40.
The affinities of the products to the enzyme could not be determined
enzymatically and were thus estimated by averaging the values known for
Trypanosmoma brucei, Lactococcus lactis & human erythrocytes (Table 4.5.).
The basis for this estimation is the assumption that active sites are conserved,
although this may not always be the case. This method, however, is expected
to provide a Km value that is more accurate than choosing an arbitrary value.
Where vALD is the reaction rate, Vf is the maximal forward rate, dhap,
gap, f16dp are the DHAP, GAP and F1,6DP concentrations, Kmgap, Kmdhap,
Kmf16dp are Michaelis constants for GAP, DHAP and F1,6DP and Keq is the
equilibrium constant of the reaction.
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Table 4.5: Experimentally determined and estimated kinetic parameters for P.
falciparum aldolase. See text for details.
Metabolite Km(mM) Reference Km(mM) Reference
F16BP 0.078 ± 0.01 This work 0.025 ± 0.006 40
DHAP 0.11 ± 0.0891 61,62,64
GAP 0.046 ± 0.0191 61,62,64
Equation Parameters
Vmax(forward) 0.311 ± 0.0354 µmol.min−1.mg protein−1 This work
Keq 0.090 mM 89
1 Estimated by averaging value of affinities in Trypanosmoma brucei,
Lactococcus lactis & human erythrocytes.
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Figure 4.3: Kinetic characterisation of P. falciparum aldolase in terms of its
substrate, fructose 1,6-bisphosphate. Data is fitted to the Michaelis-Menten
equation. Error bars indicate standard deviation of the mean (n = 3).
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4.1.6 Triosephosphate Isomerase
Triosephosphate isomerase could not be enzymatically characterised in terms of
substrate or product affinities. TPI was modeled using a reversible generic rate
equation (Eq. 4.1.8) and the kinetic parameters were obtained from literature
or estimated from T. brucei and human erythrocytes (Table 4.6).
vTPI =
Vf · dhap(1− gapdhap·Keq )
Kmdhap(1 +
dhap
Kmdhap
+ gapKmgap )
(4.1.8)
Where vTPI is the reaction rate, Vf is the maximal forward rate, dhap, gap
are the DHAP and GAP, Kmgap, Kmdhap are Michalis constants GAP and
DHAP and Keq is the equilibrium constant of the reaction.
Even though Vmax values could be measured reproducibly for the forward
and reverse reactions, complete saturation curves could not be obtained.
This may be due to the assay approach used (see Methods 4.1) where the
conversion of GAP to DHAP (reverse reaction) was linked to the the oxidation
of NADH in the presence of α-glycerolPDH. In this assay protocol the oxidation
of NADH would allow G3PDH reaction to utilise its substrate GAP in
the presence of the produced NAD+. Ultimately, this would result in the
underestimation of the TPI rate.
Table 4.6: Kinetic parameters obtained for P. falciparum Triosephosphate
isomerase.
Metabolite Km(mM) Reference
DHAP 1.0 ± 0.261 61,64
GAP 0.35 ± 0.16 136
Equation Parameters
Vmax(forward) 0.285
2 This work
Vmax(reverse) 2.198 ± 0.0426 This work
Keq 0.045 155
1 Average value of affinities for Trypanosmoma brucei & human erythrocytes.
2 Determined using the Haldane relationship
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At low non-saturating concentrations of GAP, the rate of TPI and G3PDH
would approach equality and thus the rate of TPI would approach zero (no net
oxidation of NADH). Since the G3PDH reaction requires inorganic phosphate,
assays in future will be performed in the absence of phosphate. The forward
reaction rate (DHAP converted to GAP) could not be reproducible measured
under saturating concentrations of substrate, and was not detected at lower
concentrations of substrate.
This may be due to the fact that the rapid TPI reaction converts GAP to
DHAP (thermodynamically favourable) and consequently aldolase converts
GAP and DHAP to F1,6BP (also thermodynamically favourable). To test
if this indeed the case, higher concentrations of G3PDH will be tested, such
that this reaction rate is far greater than the TPI and ALD rates.
4.1.7 Glyceraldehyde 3-phosphate Dehydrogenase
Characterisation of Plasmodium glyceraldehyde 3-phosphate dehydrogenase
has not been published. In this work G3PDH was characterised in the reverse
direction (Fig. 4.4) using 3PGA and NADH as substrates.
3PGA was assumed to be entirely converted to the chemically unstable 1,
3BPG. This assumption may not be entirely true and thus the estimated Km
(Table 4.7) is expected to be lower than calculated.
Once the model is fully validated parameter sensitivity analysis (see General
Discussion, Chapter 5) will be used to determine if an underestimation of this
parameter has a significant effect on model outcome. The forward reaction
could not be measured reproducibly for reasons mentioned previously (see
Section 4.1.6.)
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A generic reversible bisubstrate rate equation 4.1.9 was used to describe
G3PDH where vG3PDH is the reaction rate, Vf is the maximal forward rate,
nad, gap, nadh, bpg are the NAD+, GAP, NADH and 1, 3BPG concentrations,
Kmgap, Kmnad,Kmnadh,Kmbpg are Michaelis constants for GAP, NAD+, NADH
and DPG and Keq is the equilibrium constant of the reaction.
vG3PDH =
Vf · gap · nad · (1− bpg·nadh(gap·nad·Keq )
Kmgap ·Kmnad(1 + gapKmgap +
bpg
Kmbpg
)(1 + nadKmnad +
nadh
Kmnadh
)
(4.1.9)
Table 4.7: Kinetic parameter values determined and estimated for P. falciparum
glyercaldehyde 3-phosphate dehrdrogenase.
Metabolite Km(mM) Reference
GAP 0.20 ± 0.0711 61,62
NADH 0.043 ± 0.0051 This work
NAD 0.33 ± 0.181 61,62
1,3BPG 0.07 ± 0.019 This work
Equation Parameters Reference
Vmax(forward) 0.346
2 µmol.min−1.mg protein−1 This work
Vmax(reverse) 0.214 ± 0.0807 µmol.min−1.mg protein−1 This work
Keq 0.487 33
1 Average value of affinities for Trypanosmoma brucei & Lactococcus lactis
2 Determined using the Haldane relationship.
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Figure 4.4: Characterisation of P. falciparum glyceraldehyde 3-phosphate dehy-
drogenase in terms of its products. A) Since the substrate 1,3BPG is chemically
unstable, 3PGA in the presence of excess PGK and ATP is used to produce 1,3BPG.
It is assumed that the majority of 3PGA is converted to 1,3BPG. B) NADH is
varied between 0 and 0.5 mM in the presence of saturating 3PGA and excess PGK
and ATP. Non-linear regression of the data with the Michaelis-Menten equation is
shown. Error bars represented standard deviation of the mean (n = 3).
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4.1.8 Phosphoglycerate Kinase
Phosphoglycerate kinase was characterised for the reverse direction using 3-
phosphoglycerate and ATP as substrates with the Km values (n = 3) being
determined to be 2.97 ± 1.77 mM and 1.41 ± 1.25 mM, respectively (results
not shown). Due to the large error in these parameter values, the kinetic
parameters, excepting enzyme activities, were obtained from literature (Table
4.8). Since 1,3BPG is chemically unstable the forward reaction was not
characterised.
No regulation is known for P. falciparum phosphoglycerate kinase and it was
described by a reversible bisubstrate rate equation (Eq. 4.1.10.).
vPGK =
Vf · bpg · adp(1− 3pga·atpbpg·adp·Keq )
Kmbpg ·Kmadp(1 + dpgKmbpg +
3pga
Km3pga
)(1 + adpKmadp +
atp
Kmatp
)
(4.1.10)
Where, vPGK is the reaction rate, Vf is the maximal forward rate, bpg,
adp, 3pga, atp are the 1,3BPG, ADP, 3PGA and ATP concentrations, Kmbpg,
Kmadp,Km3pga,Kmatp are Michaelis constants for 1,3BPG, ADP, 3PGA and
ATP and Keq is the equilibrium constant of the reaction.
Table 4.8: Kinetic parameter values obtained for P. falciparum 3-phoshoglycerate
kinase.
Metabolite Km(mM) Reference
1,3BPG 0.0134 118
ADP 0.300 118
3PGA 0.17 118
ATP 0.68 118
Equation Parameters Reference
Vmax(forward) 30.89
1 µmol.min−1.mg protein−1 This work
Vmax(reverse) 0.470 ± 0.0075 µmol.min−1.mg protein−1 This work
Keq 1890 33
1 Determined using the Haldane relationship.
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4.1.9 Phosphoglycerate Mutase
Phosphoglycerate mutase, which has not been characterised for Plasmodium
previously, was characterised in terms of both its substrate and product (Fig
4.5). The determined the kinetic parameters presented in table 4.9. The
enzyme rate was described by a reversible Michaelis-Menten equation (Eq.
4.1.11.)
The equilibrium constant determined using the Haldane relationship (Table
4.9.) is approximately 18 times less than expected. No explanation can be
offered for this significant difference and in future work each of the parameters
will be redetermined in an attempt to resolve the issue.
vPGM =
Vf · 3pga(1− pga2pga3·Keq )
Km3pga(1 + 3pgaKm3pga +
2pga
Km2pga
)
(4.1.11)
Where, vPGM is the reaction rate, Vf is the maximal forward rate, 3pga,
2pga are the 3PGA and 2PGA concentrations, Km3pga, Km2pga are Michaelis
constants for 3PGA and 2PGA and Keq is the equilibrium constant of the
reaction.
Table 4.9: Kinetic parameters experimentally determined for P. falciparum
phosphoglycerate mutase.
Metabolite Km(mM) Reference
3PGA 2.7 ± 0.39 This work
2PGA 0.33 ± 0.029 This work
Equation Parameters Reference
Vmax(forward) 0.601 ± 0.0723 µmol.min−1.mg protein−1 This work
Vmax(reverse) 0.133 ± 0.0235 µmol.min−1.mg protein−1 This work
Keq 9.8 89 0.551 This work
1 Determined using the Haldane relationship.
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Figure 4.5: Kinetic characterisation of P. falciparum PGM in terms of substrate
and product. A) Substrate 3-phosphoglycerate was varied between 0-25 mM. B) 2-
Phosphoglycerate was varied between 0-5 mM. Fitting with the Michaelis-Menten
equation (shown) was used to determine Vmax and Km values. Standard deviation
of the mean (n = 3) is indicated with error bars.
In the model the Vmax(forward) parameter value is used as it was considered
more accurate than the reverse reaction rate. This assumption was based on
the fact that the forward assay is linked via thermodynamically favourable
reactions catalysd by ENO, PK and LDH, compared to the less favourable
reverse reactions.
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4.1.10 Enolase
P. falciparum enolase was characterised for its substrate and product (Figs.
4.6 and 4.7, respectively). Kinetic parameters determined by fitting the
experimental data to a reversible Michaelis-Menten equation (Eq. 4.1.12.)
are displayed in Table 4.10.
vENO =
Vf · 2pga(1− pep2pga·Keq )
Km2pga(1 + pepKmpep +
pga2
Km2pga
)
(4.1.12)
Where, vENO is the reaction rate, Vf is the maximal forward rate, 2pga, pep
are the 2PGA and PEP concentrations, Km2pga, Kmpep are Michaelis constants
for 2PGA and PEP and Keq is the equilibrium constant of the reaction.
The affinities of substrate and product determined in this work are both
approximately a quarter of those determined by Pal et al 106. The discrepancy
may be due to the fact that Pal used recombinant P. falciparum NF54 enolase
and an optimum enzyme activity pH of 7.4.
Table 4.10: Kinetic parameters determined for P. falciparum enolase.
Metabolite Km(mM) Reference Km(mM) Reference
2PG 0.010 ± 0.0026 This work 0.041 ± 0.004 106
PEP 0.63 ± 0.17 This work 0.25 ± 0.03 106
Equation Parameters Reference
Vmax(forward) 0.346 ± 0.019 µmol.min−1.mg protein−1 This work
Vmax(reverse) 0.151 ± 0.020 µmol.min−1.mg protein−1 This work
Keq 4.6 89 44.11 This work
1 Determined using the Haldane relationship.
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Figure 4.6: P. falciparum enolase was kinetically characterised in terms of
its substrate 2-phosphoglycerate. Kinetic parameters (Vmax and Km) were
determined by fitting with the Michaelis-Menten equation (shown). Error bars
represent standard deviation of the mean (n = 3).
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Figure 4.7: P. falciparum enolase was kinetically characterised in terms of
its product, phosphoenolpyruvate. Kinetic parameters (Vmax and Km) were
determined by fitting with the Michaelis-Menten equation (shown). Error bars
represent standard deviation of the mean (n = 3).
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4.1.11 Pyruvate Kinase
Pyruvate kinase was assumed to be irreversible, inhibited by ATP and
described by Eq. 4.1.13. PK was characterised in this work, but due to lack
of reproducibility and large error the kinetic parameters (except Vmax) that
were used in the kinetic model were obtained from literature (Table 4.11.).
vPK =
Vf · pep · adp
Kmpep · adp(1 + atpKiatp ) +Kmadp · pep+ adp · pep)
(4.1.13)
Where, vPK is the reaction rate, Vf is the maximal forward rate, adp, pep,
atp are the ADP, PEP and ATP concentrations, Kmadp, Kmpep are Michaelis
constants for ADP and PEP and Kiatp is the inhibition constant of ATP.
Table 4.11: Kinetic parameters obtained from literature for P. falciparum pyruvate
kinase.
Metabolite Km(mM) Reference
PEP 0.190 ± 0.028 27
ADP 0.126 ± 0.043 27
Equation Parameters Reference
KiATP 1.0 mM1 27
Vmax(forward) 0.756 ± 0.0147 µmol.min−1.mg protein−1 This work
1 Estimated from (Fig. 5.) in Chan et al27.
4.1.12 Lactate Dehydrogenase
P. falciparum lactate dehydrogenase was characterised in terms of its sub-
strates and products (Figs. 4.8. & 4.9. respectively). A bisubstrate reversible
generic rate equation (Eq. 4.1.14.) was used to describe the LDH reaction,
with the determined kinetic parameters shown in Table 4.12.
vLDH =
Vf · pyr · nadh · (1− Lacint·nadpyr·nadh·Keq )
(Kmpyr ·Kmnadh)(1 + pyrKmpyr + LacintKmpyr )(1 + nadKmnad + nadhKmnadh )
(4.1.14)
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Where, vLDH is the reaction rate, Vf is the maximal forward rate, pyr,
nadh, nad, Lacint are the pyruvate, NADH, NAD+ and internal lactate
concentrations, Kmpyr, Kmnadh, Kmnad, KmLacint are Michaelis constants
for pyruvate, NADH, NAD+ and internal lactate and Keq is the equilibrium
constant of the reaction.
Table 4.12: Kinetic parameters determined for P. falciparum lactate dehydroge-
nase.
Metabolite Km(mM) Ref. Km(mM) Ref. Km(mM) Ref.
Pyr 0.089 ± 0.016 This work 0.055 133 0.030 56
NADH 0.0302 ± 0.0065 This work 0.011 133 0.007 56
Lac 2.39 ± 0.42 This work 47 133 12 56
NAD+ 0.200 ± 0.066 This work 0.180 133 0.086 56
Equation Parameters Ref.
Vmax(forward) 1.280 ± 0.0871 µmol.min−1.mg protein−1 This work
Keq 10684 159
KiPyruvate 140 ± 18 mM 133
The Km values determined for pyruvate, NADH and NAD+ in this and other
works (see Table 4.12.) are all within the same order of magnitude, with
differences being ascribed to varying assay pH.
Gomez et al 56 used a pH of 9.2 for the characterisation of NAD+, pyruvate
and lactate affinity and a pH of 7.5 for NADH, while Shoemark et al 133 used
a pH of 7.5 for both substrates and products. These different assay conditions
may also provide a reason for the large variation in the affinity of lactate for
LDH, which varies between 2 and 50 mM.
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Figure 4.8: P. falciparum lactate dehydrogenase characterised in terms of its
substrates. A) Characterisation of NADH binding under saturating pyruvate
concentrations. B) Pyruvate concentration was varied under saturating NADH
concentrations . Fitting with the Michalis-Menten equation (shown) produced
Vmax and Km values. Standard deviation of the mean (n=3) is indicated by
means of error bars.
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Figure 4.9: Kinetic characterisation of P. falciparum lactate dehydrogenase in
terms of its products A) NAD+ and B) lactate. Product concentrations were varied
under saturating concentrations of the other product. To determine the kinetic
parameters, the data were fitted to the Michaelis-Menten equation. Standard
deviation of the mean is indicated by error bars (n = 3).
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4.1.13 Lactate Transporter
The transport of lactate in P. falciparum has been studied previously43 and
the kinetic parameters, where possible were obtained from literature (Table
4.13.) The transporter was assumed to bind rapidly as well as reversibly and
symmetrically (Eq. 4.1.15.)
vLacTransport =
Vf · Lacex(1− LacexKeq ·Lacint )
KmLacint(1 +
Lacex
KmLacex
+ LacintKmLacint
)
(4.1.15)
Where, vLac is the reaction rate, Vf is the maximal forward rate, Lacex, Lacint
are the external and internal lactate concentrations, KmLacex , KmLacintare
Michaelis constants for external and internal lactate and Keq is the equilibrium
constant of the reaction.
Table 4.13: Kinetic parameter values obtained from literature for the P.
falciparum lactate transporter.
Metabolite Km(mM) Reference
Lacexternal 3.8 ± 0.8 43
Lacinternal 3.81
Equation Parameters Reference
Vmax(forward) 1.5
2 µmol.min−1.mg protein−1 This work
Keq 1.0
1 Assumed symmetrical binding.
2 Assumed to be rapid.
4.2 Maximal enzyme rates
The maximal rates of each glycolytic enzyme were all determined (except for
the transporters) from a homogenate of trophozoite lysates to counter variation
in protein expression levels between batches. Each of the Vmax parameter
values have been displayed in the preceding section, but are summarised here
in Table 4.14. for comparison. Since all of the Vmax values are determined
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from a single homogenate on the same day loss of enzyme activity may occur
for some enzymes. This may indeed be the case for many of the enzymes where
measured maximal enzyme activities are far lower than when determined from
saturating curves. Loss of enzyme activity during storage and during enzyme
activity assays will be investigated.
Table 4.14: Experimentally determined maximal enzyme rates for the glycolytic
enzymes in Plasmodium falciparum. Rates are normalised to total protein content
and standard deviation of triplicate values determined in a single experiment is
indicated.
Enzyme Maximal Rate (mmol·min−1·mg protein−1)
Forward Reverse
GlucTr 0.01-0.12 1
HK 0.325 ± 0.0092 -
PGI 0.363 ± 0.0326 0.232 ± 0.0354
PFK 0.142 ± 0.0167 -
ALD 0.311 ± 0.0354 -
TPI 0.2852 2.198 ± 0.0426
GAPDH 0.3462 0.214 ± 0.0807
PGK 30.892 0.470 ± 0.0075
PGM 0.601 ± 0.0723 0.133 ± 0.0235
ENO 0.346 ± 0.0193 0.151 ± 0.0200
PK 0.756 ± 0.0147 -
LDH 1.280 ± 0.0871 -
LacTr 1.53
1 Range of values used.
2 Determined using the Haldane relationship.
3 Assumed to be rapid.
4.3 Flux Determinations
An important part of any kinetic modeling is validation. In this study
we partially validated the kinetic model (see next Chapter) by comparing
measured fluxes and the steady state flux predicted by the model (Table 4.15).
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The in vivo flux was measured by incubating intact trophozoites in a buffer
containing glucose and measuring the rate of glucose consumption and lactate
production (Fig. 4.10). Not all the glucose is consumed and the consumption
rate decreases after approximately 3 hours. This may be due to the decrease
in pH of the medium since 15 mM of lactate are produced in a 25 mM HEPES
buffer, but this hypothesis has yet to be tested.
It should be noted that the trophozoites were found to be extremely sensitive
to the saponin isolation protocol. Trophozoites were removed from saponin
contact as soon as possible, in order to maintain membrane integrity and
membrane potential. Failure to do so resulted in negligible glycolytic flux
(results not shown).
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Figure 4.10: Utilisation of glucose and production of lactate in saponin isolated
P. falciparum trophozoites. Linear regression over the first 3 hours of incubation
(R2 > 0.97), yielded flux rates (Table 4.15), where the lactate production rate is
approximately double the glucose consumption rate. Lactate data representative
of triplicate and glucose in duplicate experiments.
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The linear consumption and production rate of glucose and lactate over a
period of 3 hours, respectively, were used as the glycolytic fluxes (Table 4.15).
The ratio of the production and consumption rates is approximately 2.2, which
shows that the assumption that 1 mol glucose is entirely converted to 2 mol
lactate, with negligible flux through alternative pathways, is valid.
Table 4.15: Glucose consumption and lactate production rates of intact isolated
P. falciparum trophozoites incubated in a glucose medium over a period of 3 hours.
Metabolite Rate (mmol·min−1·mg protein−1)
Glucose 0.0487
Lactate 0.1065
Lactate : Glucose Ratio 2.186
Whether this flux is in steady state is unknown, since the metabolite
concentrations were not measured. A constant flux is not an indicator of steady
state, as one could still find slow accumulation of one or more intermediates.
At steady state the internal metabolite concentrations would be constant. The
method for the determination of the glycolytic intermediates was established
(Section 4.4) and future work will include full validation of the model with
steady state metabolite concentrations.
4.4 Method Development: Measuring Intermediate
Concentrations
Measuring the internal metabolites is of the utmost importance for validating
the model. Glycolytic intermediates were determined enzymatically by
adapting a protocol described by Maitra et al 92. The advantage of the
enzymatic determinations, is their accuracy and simplicity and it was impor-
tant to determine the sensitivities of the assays, as parasite concentrations in
incubations are generally lower than those used for yeast or bacteria.
All the intermediates were determined in four separate stepwise assays where
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20 µL sample/standard was added to 80 µL assay buffer (described previously)
containing various enzymes and cofactors. G6P was determined by incubating
standards or samples in assay buffer containing NADP (2 mM) and G6PDH
(20 U/mL) for 10 min, after which the absorbance was measured at 340 nm.
Once the absorbance was recorded, F6P was determined by adding PGI (20
U/mL) and incubated for a further 10 min and measuring absorbance at 340
nm.
In a similar step wise manner, DHAP, GAP and FBP were determined by
incubating the samples/standards in buffer containing NADH (2 mM) and α-
glyceroPDH (20U/mL). Following a 30 minute incubation period, absorbance
was measured, followed by the addition of TIM (50U/mL) and a further 30
min incubation period. Lastly FBP was determined by the addition of ALD
(20 U/mL) and a 10 min incubation.
3PGA and 2PGA were determined by incubating samples/standards in assay
buffer containing NADH (2mM), GAPDH (20 U/mL) and ATP (4 mM).
Absorbance was read at 340 nm after a 20 min incubation period, after which
2PGA was determined by the addition of PGM (10 U/mL) and a 20 incubation
period.
PEP and pyruvate were determined incubating standards or samples in assay
buffer containing LDH (20 U/mL), NADH (2mM) for 20 min and reading the
absorbance at 340nm. Pyruvate was determined by the addition of PK (20
U/mL) and ADP (4mM) and incubating for 25 minutes before reading the
absorbance at 340 nm.
Incubation times were determined by monitoring the change in absorbance at
340 nm over time until the rate became zero.
Satisfactory calibration curves were obtained for all the glycolytic inter-
mediates (Figures 4.11 and 4.12), except for GAP. The protocol rendered
sensitivities (down to 10 µM) for G6P, F6P, PEP and pyruvate and below
100 µM for F 1,6BP and 2PGA. Concentrations of DHAP and 3PGA below
0.3 mM could not be accurately determined.
This protocol was tested on Plasmodium incubations, but metabolites were
not detectable, due to cell concentration (108trophozoites/mL) being too low.
Assuming a 30 fL volume for a trophozoite 35 hours post-invasion2 and
the desired ability to measure > 100 µM, and taking into account dilution
due to extraction procedures, one would have to incubate at extremely high
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Figure 4.11: Calibration curves obtained from the method established for the
enzymatic determination of glucose 6-phosphate, fructose 6-phoshate, fructose
1,6-bisphosphate and dihydroxyacetone phosphate. Data shown with a linear fit
(R2 > 0.99) is from a single experiment, but trends are representative of duplicate
assays.
concentrations of approximately 1010 trophozoites/mL. Culturing such large
numbers of parasites is not feasible with 109 trophozoites/mL, being more
appropriate. Since sample volume and assay sensitivity have been shown to be
linear92, one could increase the assay sensitivity approximately two fold. This
method, should thus theoretically be suitable for measuring internal metabolite
concentrations in Plasmodium above 500µM. Some of the intermediates
present at low concentrations, such as the phoshopglycerates may not be
detectable. For these metabolites more sensitive detection methods, such as
mass spectrometric detection protocols described in16,151, could be used.
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Figure 4.12: Calibration curves obtained from the method established for the
enzymatic determination of 3 and 2-phosphoglycerate, phosphoenolpyruvate and
pyruvate. Data shown with linear fit (R2 > 0.99, except for phosphoglycerates:
R2 > 0.9) is from a single experiment, but trends are representative of duplicate
assays.
Chapter 5
Theoretical Results and
Discussion
This chapter presents the theoretical aspects of this work, which include
the construction and validation of a detailed kinetic model for P. falciparum
glycolysis. The experimental results used for the construction and validation
of the model were presented in the preceding chapter.
5.1 Kinetic Model Construction
The homolactic fermentation of glucose was modelled in thirteen reaction steps
(Fig. 5.1). The model consists of a set of ordinary differential equations
(Eqns 5.1.1 - 5.1.16), which describe the change in glycolytic metabolite
concentrations over time as a function of enzyme rates (Eqns 5.1.17 - 5.1.30).
glu′[t] = v0Glutr − v1HK (5.1.1)
g6p′[t] = v1HK − v2PGI (5.1.2)
f6p′[t] = v2PGI − v3PFK (5.1.3)
f16dp′[t] = v3PFK − v4ALD (5.1.4)
dhap′[t] = v4ALD − v5TIM (5.1.5)
gap′[t] = v4ALD + v5TIM − v6G3PDH (5.1.6)
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bpg′[t] = v6G3PDH − v7PGK (5.1.7)
3pga′[t] = v7PGK − v8PGM (5.1.8)
2pga′[t] = v8PGM − v9ENO (5.1.9)
pep′[t] = v9ENO − v10PK (5.1.10)
pyr′[t] = v10PK − v11LDH (5.1.11)
lac′[t] = v11LDH − v12LACtr (5.1.12)
atp′[t] = v7PGK + v10PK − v1HK − v3PFK − v13atp(5.1.13)
adp′[t] = v1HK + v3PFK − v7PGK − v10PK + v13atp(5.1.14)
nadh′[t] = v6G3PDH − v11LDH (5.1.15)
nadh′[t] = v11LDH − v6G3PDH (5.1.16)
The transporter rates v0Glutr (Eq. 5.1.17.)and v12LACtr (Eq. 5.1.29.)
describe the transport of glucose and lactate across the parasite membrane
and into or out of the parasite cytosol, respectively. The enzyme rates
v1HK (hexokinase, Eq. 5.1.18.), v2PGI (phosphoglucoisomerase, Eq. 5.1.19.),
v3PFK (phosphofructokinase, Eq. 5.1.19.), v4ALD (aldolase, Eq. 5.1.21.),
v5TIM (triosephosphate isomerase, Eq. 5.1.22.), v6G3PDH (glyceraldehyde
phosphate dehydrogenase, Eq. 5.1.24.), v7PGK (phosphoglycerate kinase, Eq.
5.1.24.), v8PGM (phosphoglycerate mutase, Eq. 5.1.25.), v9ENO (enolase,
Eq. 5.1.26.), v10PK (pyruvate kinase, Eq. 5.1.27.) and v11LDH (lactate
dehydrogenase, Eq. 5.1.28.) describe the modelled enzymatic reactions.
Each enzyme rate (Eqns 5.1.17 - 5.1.30) is described using reversible or
irreversible uni-substrate Michaelis-Menten equations or bi-substrate generic
rate equations116, except in the cases of i) v3PFK which uses a Monod-
Wyman-Changreux equation obtained from Buckwitz et al 17 and ii) v10PK
which is a Ping-Pong Bi-Bi kinetic equation.
In P. falciparum the activities of PFK and PK are allosterically regulated.
The rate equation v3PFK contains allosteric regulation in the forms of PEP
activation and ATP inhibition and competitive by ADP.
P. falciparum pyruvate kinase is inhibited by ATP, but this has only been
partially characterised by Chan et al 27 who showed that ATP is competitive
with respect to PEP. The inhibition mechanism of ATP with respect to ADP
is unknown, but was assumed to be uncompetitive and thus v10PK follows a
ping-pong bi-bi rate mechanism and includes inhibition by ATP.
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Figure 5.1: Schematic representation of the glycolytic pathway in P. falciparum,
where glucose is entirely converted to lactate and ATP. Enzymes are indicated
by red circles, clamped metabolites in green text, and erythrocyte and parasite
compartments in different shades of grey.
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The kinetic parameter values that were used in the rate equations are
summarised in Table 5.1. See Section 4.1 for specific details of how the
constants were determined.
Since the complete conversion of glucose to lactate results in a net production
of 2 mol ATP per mol glucose an ATP demand reaction (v13atp, Eq. 5.1.30)
was included to prevent the accumulation of ATP and thus make a steady
state possible. v13atp is a Michaelis-Menten type equation, which acts as an
ATPase. The parameter values used for the ATPase reaction (both Vmax and
Michaelis constant, Table 5.1.) were obtained by fitting them to obtain an
ATP/ADP ratio of five, which was observed by Fry et al 52. These parameters
were fitted as they can not be determined experimentally.
In the model all enzyme rates were expressed in µmol.min−1.mg protein−1,
time t in min and the metabolite concentrations in mM. Since the relation
between total protein concentration and cytosolic volume could not be
determined, there is an inconsistency between the units of the maximal rates
and metabolite concentrations. This restricts the current model to steady state
evaluations, as were used in the work presented in this thesis. In future, to
allow for time integration of the model, the relation between total protein and
cytosolic volume will be determined. This relation will allow the maximal rates
to be expressed as mM·min−1 and thus maintain dimensional consistency.
v0Glutr =
(V GLUtr · gluex(1− glu[t]gluex·Kv0eq )
Kv0glutr(1 + gluexKv0glutr +
glu[t]
Kv0Gluint)
(5.1.17)
v1HK =
V HK · glu[t] · atp[t]
Kv1glu ·Kv1atp(1 + glu[t]Kv1glu)(1 + atp[t]Kv1atp)
(5.1.18)
v2PGI =
V PGI · g6p[t](1− f6p[t]g6p[t]·Kv2eq )
(Kv2g6p(1 + g6p[t]Kv2g6p +
f6p[t]
Kv2f6p)
(5.1.19)
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v3PFK =
V PFK · atp[t] · f6p[t]
(atp[t] +Kv3atp(1 + adp[t]Kv3adp))(f6p[t] +Kv3f6p)
(
1
1 + v3Lo
)
v3Lo = v3L(
(1 + v3MgKv3mg )(1 +
atp[t]
Kv3atp)
(1 + f6p[t]Kv3f6p2)(1 +
pep[t]
Kv3pep)
)v3n (5.1.20)
v4ALD =
V ALD · f16dp[t](1− dhap[t]·gap[t]f16dp[t]·Kv4eq )
Kv4f16dp(1 + f16dp[t]Kv4f16dp +
dhap[t]
Kv4dhap +
gap[t]
Kv4gap +
gap[t]·dhap[t]
Kv4gap·Kv4dhap)
(5.1.21)
v5TIM =
V TIM · dhap[t](1− gap[t]dhap[t]·Kv5eq )
Kv5dhap(1 + dhap[t]Kv5dhap +
gap[t]
Kv5gap)
(5.1.22)
(5.1.23)
v6G3PDH =
V G3PDH · gap[t] · nad[t] · (1− dpg[t]·nadh[t](gap[t]·nad[t]·Kv6eq )
(Kv6gap ·Kv6nad)(1 + gap[t]Kv6gap + dpg[t]Kv6dpg (1 + nad[t]Kv6nad + nadh[t]Kv6nadh)
v7PGK =
V PGK · dpg[t] · adp[t](1− pga3[t]·atp[t]dpg[t]·adp[t]·Kv7eq )
Kv7dpg ·Kv7adp(1 + dpg[t]Kv7dpg + pga3[t]Kv7pga3)(1 + adp[t]Kv7adp + atp[t]Kv7atp)
(5.1.24)
v8PGM =
V PGM · pga3[t](1− pga2[t]pga3[t]·Kv8eq )
Kv8pga3(1 + pga3[t]Kv8pga3 +
pga2[t]
Kv8pga2)
(5.1.25)
v9ENO =
V ENO · pga2[t](1− pep[t]pga2[t]·Kv9eq )
Kv9pga2(1 + pep[t]Kv9pep +
pga2[t]
Kv9pga2)
(5.1.26)
v10PK =
V PK · pep[t] · adp[t]
Kv10pep · adp[t](1 + atp[t]Kiv10) +Kv10adp · pep[t] + adp[t] · pep[t])
(5.1.27)
v11LDH =
V LDH · pyr[t] · nadh[t] · (1− lac[t]·nad[t]pyr[t]·nadh[t])·Kv11eq )
(Kv11pyr ·Kv11nadh)(1 + pyr[t]Kv11pyr + lac[t]Kv11pyr )(1 + nad[t]Kv11nad + nadh[t]Kv11nadh)
(5.1.28)
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v12LACtr =
V LACtr · lac[t]
lac[t] +Kv12lac
(5.1.29)
v13ATP =
v13katp · atp[t]
Kv13atp+ atp[t]
(5.1.30)
5.1.1 Starting Conditions
In the model external metabolite concentrations were clamped and initial
internal metabolite concentrations were set as explained below.
External glucose was clamped at 3 mM, which is lower than concentrations
found in human plasma (5mM)1, but glucose concentrations within the
erythrocyte and between the parsasite parasitiphorous and plasma membrane
are assumed to be lower. The external lactate concentration was fixed at 2
mM, similar to concentrations measured in uninfected red blood cells147.
Since the external metabolites concentrations (mM) were clamped, the change
in concentration due to compartment volume change (erythrocyte to parasite),
was ignored. In future, if compartments are explicitly modeled the volume
change will be taken into account.
Three moieties are found in the branch of glycolysis, namely (ATP + ADP),
(NAD + NADH) and (DPG + 3PGA + 2PGA + PEP + Pyr + NAD). The
initial conditions for the metabolites in the latter branch were set, such that the
sum is approximately 5 mM. Once internal metabolites have been measured,
the sum of the metabolite concentrations in the moiety can be adjusted to the
sum of those experimentally determined. The NAD/NADH moiety was set to
4 mM and the sum of ATP and ADP set to 1.2 mM141.
The initial glycolytic intermediate concentrations for the model (Table 5.2)
were obtained by clamping ATP/ADP at a ratio of five and using the steady
state metabolite concentrations determined in this clamped state as starting
conditions in the unclamped model.
C
hapter
5.
T
heoreticalR
esults
and
D
iscussion
84
Table 5.1: Kinetic parameters used for the construction of the kinetic model, obtained in this work or from literature (See Chapter
4.1 for details). The parameters have been renamed such that each parameter name contains the reaction number that it applies to
as well as an abbreviation of the metabolite name.
Reaction Kinetic Equation Parameters Values (mM) Reference
v0GlucTr Kv0glutr 0.97 ± 0.34 Kv0Gluint1 1.0 71
v1HK Kv1glu2 0.14 ± 0.017 Kv1atp 0.57 ± 0.06 This work
v2PGI Kv2g6p 0.92 ± 0.098 Kv2f6p2 0.081 ± 0.003 This work
v3PFK Kv3f6p 0.034 Kv3atp 0.028 Kv3adp 0.17 Kv3pep 0.13 17
v3PFK Kv3f6p2 0.054 Kv3mg 0.78 v3L 3.22 v3n 3.92 17
v4ALD Kv4f16dp 0.078 ± 0.01 Kv4dhap3 1.0 Kv4gap.3 1. 0 This work
v5TPI Kv5gap 0.35 ± 0.16 Kv5dhap3 1.0 136
v6G3PDH Kv6nadht 0.043 ± 0.005 Kv6dpg2 0.07 ± 0.019 Kv6gap3 0.10 Kv6nad3 0.10 This work
v7PGK Kv7dpg 0.0134 Kv7adp 0.300 Kv7pga3 0.17 Kv7atp 0.68 118
v8PGM Kv8pga32 2.7 ± 0.39 Kv8pga22 0.33 ± 0.029 This work
v9ENO Kv9pep∗ 0.25 ± 0.03 Kv9pga22 0.013 ± 0.002 ∗ 107,This work
v10PK Kv10pep 0.190 ± 0.028 Kv10adp 0.126 ± 0.043 Kiv104 1.0 27
v11LDH Kv11nad 0.200 ± 0.066 Kv11pyrt 0.089 ± 0.016 This work
v11LDH Kv11nadh 0.0302 ± 0.007 Kv11lac2 2.39 ± 0.42 This work
v12LacTr Kv12lac3 3.8 Kv12lacex 3.8 ± 0.8 43
v13ATPase Kv13atp 0.25 v13katp 0.14055 Fitted
1 Assumed symmetrical binding.
2 Determined in triplicate in a single experiment.
3 Parameters not available and were thus estimated.
4 Estimated from (Fig. 5.) in27.
5 The ATPase reaction parameters were fitted to obtain an ATP/ADP ratio of 5.
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Table 5.2: These metabolite concentrations were used as initial starting
concentrations in the model.
Metabolite Concentration (mM)
GlucoseExternal 3
GlucoseInternal 0.1
G6P 10.
F6P 4.0
F1,6BP 1.0
DHAP 2.0
GAP 0.1
DPG 0.1
PGA3 0.5
PGA2 0.1
PEP 0.1
Pyr 2.0
Lac 2.0
NADH 0.2
NAD 3.8
ATP 1.0
ADP 0.2
Lactateinternal 2
5.2 Model Fitting and Validation
An important part of any kinetic modeling is validation, where data used for
validation should be unique and distinct from data used for model construction.
Additionally, if model parameters are fitted to the validation data set, further
validation with unique data is required to prevent the model merely being able
to describe a single set of conditions. Ideally one would want a model that
could predict systemic behaviour over a wide range of conditions.
In this study, enzymes were individually characterised and these kinetic data
were used to describe the individual reactions of glycolysis. By linking the
reactions together, (e.g using a set of ordinary differential equations) in a
kinetic model it is possible to predict how the pathway acts as a whole, in
terms of steady state flux and metabolite concentrations. Since these system
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wide variables can be experimentally measured in vivo and are distinct from
the enzyme characterisation data, they were chosen as a means of validation
for the kinetic model.
The only kinetic parameters that were fitted in the model were those for
the ATPase reaction, which were fitted to obtain an ATP/ADP ratio of
five. Since the glucose transporter activity was not measured in this work
a range of glucose transporter rates (0.01 - 1.2 µmol.min−1.mg protein−1)
were tested in the model. This specific range of transporter rates were chosen,
as transporter rates higher than 1.2 µmol.min−1.mg protein−1 resulted in the
massive accumulation of sugar phosphate intermediates ( > 50 mM) and rates
lower than 0.01µmol.min−1.mg protein−1 resulted in an extremely low flux.
For the selected range of glucose transporter rates the model yielded steady
state lactate fluxes between 0.015 and 0.171 µmol.min−1.mg protein−1 respec-
tively, which was in the same order of magnitude as the measured fluxes.
Setting the glucose transporter rate to 0.07 µmol.min−1.mg protein−1 returned
steady state glucose and lactate fluxes of 0.0515 and 0.1030 µmol.min−1.mg
protein−1, respectively and metabolite concentrations within a physiological
feasible range. (Table 5.3.). These predicted fluxes are comparable to those
determined experimentally (0.0487 and 0.1065 µmol.min−1.mg protein−1,
respectively) in the preceding chapter.
The model can thus predict the measured glycolytic fluxes, and maintain
metabolite concentrations within a physiological range. In future the trans-
porter activity will be determined experimentally, which together with steady
state intermediate concentrations will provide a more concrete means of
validation.
5.3 Brief Model Analysis & Discussion
Although model validation is not entirely complete, some observations were
made regarding model behaviour, that may be applicable to the regulation of
P. falciparum glycolysis.
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Table 5.3: Kinetic model predictions of steady state glycolytic fluxes and
metabolite concentrations in P. falciparum where the glucose transporter rate was
set to 0.07 µmol.min−1.mg protein−1. Experimentally determined glucose (JGluTr)
and lactate (JLacTr) fluxes were 0.0487 and 0.1065 µmol.min−1.mg protein−1,
respectively (See Section 4.3 for experimental details).
Metabolite Concentration (mM) Reaction Flux (µmol.min−1.mg protein−1)
Glucose 0.046 JGluTr 0.0515
G6P 11.0 JHK 0.0515
F6P 2.01 JPGI 0.0515
F1,6BP 0.25 JPFK 0.0515
DHAP 0.61 JALD 0.0515
GAP 0.052 JTPI 0.0515
DPG 3.42 × 10−3 JG3PDH 0.1030
3PGA 0.78 JPGK 0.1030
2PGA 0.028 JPGM 0.1030
PEP 0.067 JENO 0.1030
Pyr 1.86 JPK 0.1030
Lac 2.30 JLDH 0.1030
ATP 1.00 JLacTr 0.1030
ADP 0.19 JATP 0.1030
NADH 0.14
NAD 3.86
It was noted during analyses that the low glucose transporter rate plays an
essential role in preventing the accumulation of sugar phosphates, such as G6P
and F1,6BP. Increasing the transporter rate two fold (by increasing external
glucose concentration, or the maximal rate) not only results in a higher steady
state flux, but also the accumulation of sugar phosphates (> 100mM), and an
increase in the ATP/ADP ratio (> 50). This can be countered to a certain
extent by increasing the ATP demand rate, v13ATPase, which lowers the
ATP/ADP ratio (<1), but does not sufficiently prevent the accumulation of
G6P and especially F 1,6BP.
This phenotype has been described for some yeast mutants144, which lack the
ability to inhibit HK that consequently leads to a decrease in ATP and increase
in sugar phosphate concentration. At higher transporter rates, ATP/ADP
ratio increases due to the fact that v3PFK is not sufficiently inhibited by ATP
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and its rate is higher than v4ALD, but the flux through the lower branch of
glycolysis is still enough to provide a net production of ATP.
P. falciparum may thus have mechanisms to prevent the lethal accumulation
of the sugar phosphate intermediates. Several possible ways of avoiding this
phenomenon are proposed: 1) Relying on low glucose concentrations within
the erythrocyte, 2) Having a low glucose transporter expression level to ensure
a low transport rate or 3) Inhibition of HK by G6P, which is known to
occur in some organisms98 and thus provide a measure of sensitivity to G6P
accumulation.
Models are often constructed from quantitative data obtained experimentally,
which is better than estimating or guessing parameter values, but they may
still contain experimental error. The required accuracy of model parameters
depends to a large degree on what the model is used for (e.g. qualitative
and general or accurate and precise quantitative predictions). Parameter
sensitivity analysis can be used to identify which parameters play in key role
in model behaviour and prediction. This analysis is useful for pinpointing
parameters which should be determined as accurately as possible, as well as
identifying parameter values that need not be accurate as they have little effect
on model outcome.
The kinetic model presented in this study has numerous experimental pa-
rameters, some of which were estimated or determined only in singleton.
The possibility that a single key parameter can dramatically alter the model
behaviour and prediction exists. To identify, which parameters this model
is sensitive to, a sensitivity analysis will be performed by increasing and
decreasing each parameter value, in turn as well as combinatorially, by a fixed
percentage and examining the percentage change in steady state fluxes and/or
metabolite concentrations. In this manner one can obtain a quantitative
measure of model sensitivity to specific parameters. Since a change in
parameter values may not always lead to a linear reflection on model outcome,
gradually increasing or decreasing parameter values in small increments can be
used determine stable or unstable ranges of parameters. Using these analyses
on the Plasmodium model, parameters that 1) lead to a large change or 2)
parameters near a boundary, which if crossed would significantly alter model
prediction can be identified. These parameters would then be determined as
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accurately as possible.
Although the model is not entirely complete in terms of validation, is has
be shown that in light of the project aims, the work presented in this chapter
demonstrates that the construction and validation of a kinetic model is feasible.
Chapter 6
General Discussion
The object of this study was to establish the feasibility of constructing and
validating a detailed kinetic model of glycolysis in asexual P. falciparum.
The feasibility of the study was based on the ability to obtain the required
kinetic parameters and validation data for the construction and validation of
a kinetic model. In this study Plasmodium was cultured and the glycolytic
enzymes characterised from lysates. Kinetic parameters obtained from the
study were used to construct a kinetic model, which was partially validated
using experimentally measured glycolytic fluxes. Additional validation of the
model by steady state metabolite concentrations is possible in future with the
development of an enzyme-based method to measure the majority of glycolytic
intermediates. All the criteria set in the aims of the study were met and it
can thus be concluded that it is possible to construct and validation a detailed
kinetic model of glycolysis in the asexual P. falciparum.
Brief analysis of the model revealed the sensitivity of the system to a
high glucose transport rate, which results in the accumulation of lethal
concentrations of sugar phosphates. These findings highlight the importance
of regulation, especially in the first steps of glycolysis, where enzymes are
generally insensitive to their products and ATP is first invested before a net
production in the later branch of glycolysis7. In light of this we will be
investigating the possible systems which the organism may use to prevent
lethally high sugar phoshphate concentrations. These systems may include
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the organism i) relying on low external glucose concentrations within the
erythrocyte, ii) maintaining low expression levels of the glucose transporter
or iii) having regulatory mechanisms, such as the inhibition of HK by G6P.
The construction and validation of a kinetic model, simple or complex, is just
the first step towards answering specific questions. The power of kinetic models
is that they can be used to investigate questions and test hypotheses that
could otherwise not be examined experimentally. The kinetic model presented
in this work has several applications that will be addressed in future: i)
Identification of potential drug targets using differential control analysis, where
the control structure of the erythrocyte and other human cells are compared
to that of Plasmodium in the hope that an area of high control in the parasite
corresponds to an area of low control in the erythrocyte. ii) Investigation of
the effect of parasite infection on the erythrocyte glycolytic metabolism by
integrating the Plasmodium kinetic model into an existing erythrocyte kinetic
model. A specific area of interest in the erythrocyte metabolism, would be
the concentrations of 2,3DPG, as this metabolites plays an important role in
carbon dioxide homeostasis and alterations in this metabolism, due to parasite
infection, may have important pathophysiological implications.
The modelling approach used in this work can be applied to any organism that
can be cultivated in sufficient quantities for kinetic parameter determination
and steady flux and metabolite measurements. This approach is time
consuming, since all the glycolytic enzymes require characterisation. An
alternative kinetic modelling approach that may be worth investigating and
applicable to metabolic pathways is the construction of a generic glycolytic
model(s), where parameter values are based on an average value found over a
range of organisms. This generic model could then be adapted to any organism
by of interest by including the unique regulatory properties (e.g experimentally
characterise regulatory enzymes) of the organism. Such an approach with
the addition of parameter sensitivity analysis to identify key parameters for
experimental determination, would allow researchers to construct a working
kinetic model of an organism within a shorter time span.
A model based on a generic model may not be entirely accurate, but could
still provide a tool with sufficient accuracy to analyse systemic properties or
answer specific questions. Additionally, such a model could easily be enhanced
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by the addition of experimentally determined data.
The kinetic model of P. falciparum glycolysis may be applicable to other
Plasmodium species and could be adapted for each species. Due to high
homology between species, it would be expected that the enzyme Km values
and glycolytic regulation would not vary to large degree, although enzyme
expression levels (and thus Vmax) may vary considerably. The P. falciparum
model could thus be adapted to model alternative species by simply measuring
Vmax values, incorporating them into the current kinetic model and validating
it on glycolytic fluxes and intermediate concentrations.
This study has elucidated that the construction of a kinetic model for P.
falciparum is feasible and that the completed model may lead to the further
understanding of Plasmodium glycolysis and host-pathogen relationships.
Chapter 7
Conclusion
In this study it was established that constructing a detailed kinetic model of
the asexual Plasmodium falciparum glycolytic pathway is feasible. Kinetic
parameters for the glycolytic enzymes were determined from trophozoites
lysates and in vivo fluxes were measured in intact, isolated trophozoites. Using
the determined kinetic parameters, a detailed kinetic model was constructed
and was partially validated using measured fluxes. Further validation using
steady state metabolite concentrations is possible as an enzymatic method
for the determination of glycolytic intermediates was successfully developed
with sensitivities sufficient to quantify all of the intermediate concentrations,
except GAP and the phosphoglycerates. A brief analysis of model behaviour
revealed the importance of the glucose transporter rate in preventing the
lethal accumulation of sugar phosphates and thus prompting the proposal
that further regulation may exist in the first steps of glycolysis. The kinetic
model, once fully validated, will provide a tool to identify potential drug
targets, investigate host-pathogen interaction and gain a better understanding
of glycolytic regulation.
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Appendix A
Microplate Pathlength
Determination
The pathlength of a microplate is dependent on the working volume for
each well. Since many assays are dependent on an extinction coefficient, it
is essential that the pathlength for a specific working volume is accurately
determined. In this appendices I derive (1) a general formula for calculating
the pathlength as a function of volume for any tapered well and (2) a formula
specific to Greiner bio-one Flat Bottom Microplates, catalogue numbers 655
101, 655 161 & 655 192. The specifications for this microplate can be found
at the end of the document and were obtained from:
[http://www.greinerbioone.com/en/row/files/241968/655101.pdf - last checked Dec
2008].
The volume of a tapered well can be determined by using the formula for
a truncated cone: [http://wiki.answers.com/Q/Formula_for_calculating_volume_-
of_truncated _cone - last checked Dec 2008] as given in equation .
V olume =
1
3
pi(R12 +R1 ·R2 +R22)hA (A.0.1)
Where R1 is the base radius, R2 is the top radius and h is the height of the truncated
cone.
As the volume within the well increases, the height increases and so does the top
radius. Thus, R2 is dependent on h and the relationship can be described using the
angle (θ) between the base and well wall described in equations A.0.2 and A.0.3.
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θ = ArcTan
R2 −R1
maxheight
(A.0.2)
newR2 = Tan[θ] · h+R1 (A.0.3)
We can substitute newR2 in equation A.0.5 for R2 in A and describe the well volume,
v as a function of filled height, h.
v =
1
3
hpi(R12 +R1(R1 + h · Tan[θ]) + (R1 + h · Tan[θ])2) (A.0.4)
Equation A.0.4 is not of much use, but it can be be manipulated to obtain a general
formula for pathlength height ,h, as a function of volume, v (equation A.0.5):
h =
Cot[θ]2
pi
(pi3R13Tan[θ]3 + 3pi2v · Tan[θ]4) 13 −R1Cot[θ] (A.0.5)
From the Microplate specification sheet we obtain:
R1 =
6.390
2
mm
R2 =
6.960
2
mm
maxheight = 10.90mm
Using these constant values, θ is calculated to be 0.0261408 rad from equation A.0.2
Consequently equation A.0.5 reduces to a formula specific to the Greiner bio-one flat
botton microplates:
p = 465.6(0.01808 + 0.00001384 · v) 13 − 122.2 (A.0.6)
Where the units of pathlength, p, and volume, v, are mm and µL respectively.
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